Table of Contents

1.0 CRS 2022 National GPRA Developmental Report ................................................. 1
  1.1 CRS Denominator Definitions ........................................................................... 5
     1.1.1 For All Denominators ........................................................................... 5
     1.1.2 For All Numerators ............................................................................ 5
     1.1.3 Active Clinical Population .................................................................... 5
     1.1.4 User Population .................................................................................. 6
     1.1.5 Active Clinical Plus BH Population ..................................................... 7

2.0 Performance Measure Topics and Definitions .............................................. 8
  2.1 Diabetes Group ............................................................................................. 8
     2.1.1 Diabetes: Blood Pressure Control ....................................................... 8
  2.2 Dental Group ................................................................................................ 10
     2.2.1 Access to Dental Service ...................................................................... 10
     2.2.2 Dental Sealants ................................................................................... 14
     2.2.3 Topical Fluoride ................................................................................ 15
     2.2.4 Caries Risk Assessment ..................................................................... 17
  2.3 Immunization Group ..................................................................................... 18
     2.3.1 Adult Immunizations ......................................................................... 18
     2.3.2 Childhood Immunizations .................................................................. 34
     2.3.3 Adolescent Immunizations ................................................................ 39
  2.4 Behavioral Health Group ............................................................................. 43
     2.4.1 Screening, Brief Intervention, and Referral to Treatment (SBIRT) ...... 43
     2.4.2 Substance Use Disorder (SUD) in Women of Childbearing Age ......... 45
     2.4.3 Suicide Risk Assessment .................................................................... 50
  2.5 Cardiovascular Disease Related Group .................................................... 51
     2.5.1 Weight Assessment and Counseling for Nutrition and Physical Activity ........................................................................................................... 51
     2.5.2 Physical Activity Assessment ................................................................ 54
     2.5.3 Cardiovascular Disease and Blood Pressure Control ......................... 55
     2.5.4 Appropriate Medication Therapy after a Heart Attack ......................... 58
  2.6 STD-Related Group ..................................................................................... 68
     2.6.1 HIV Screening ..................................................................................... 68
     2.6.2 HIV Quality of Care .......................................................................... 72
     2.6.3 Hepatitis C Screening ......................................................................... 75
     2.6.4 Chlamydia Testing ............................................................................. 80
     2.6.5 STI Screening .................................................................................... 85
  2.7 Other Clinical Measures Group .................................................................. 89
     2.7.1 Proportion of Days Covered by Medication Therapy ......................... 89
     2.7.2 Concurrent Use of Opioids and Benzodiazepines .............................. 99
     2.7.3 Medication Therapy Management Services ...................................... 101
2.7.4 Optometry........................................................................................................ 101

Acronyms................................................................................................................... 103

Contact Information .................................................................................................. 105
1.0 CRS 2022 National GPRA Developmental Report

The following performance measures will be reported in the Clinical Reporting System (CRS) 2022 National Government Performance and Results Act of 1993 (GPRA)/GPRA Modernization Act (GPRAMA) Report.

**Note:** Beginning FY 2010, GPRA Developmental Measures are reported in its own separate section within the National GPRA/GPRAMA report but are not submitted to the Office of Management and Budget (OMB) and Congress. This document contains only the GPRA Developmental performance measure lists and definitions.

Notations used in this document are described in Table 1-1.

Table 1-1: Document notations

<table>
<thead>
<tr>
<th>Notation</th>
<th>Location</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section Symbol (§)</td>
<td>Preceding a measure</td>
<td>A GPRA Developmental measure. GPRA Developmental measures have the potential to become GPRA measures in the future.</td>
</tr>
<tr>
<td>Plus Symbol (+)</td>
<td>Preceding a measure</td>
<td>The measure is a new GPRA Developmental Measure for 2022.</td>
</tr>
<tr>
<td>Asterisk (*)</td>
<td>Anywhere in a code (CPT, POV, Edu, Etc.)</td>
<td>A &quot;wildcard&quot; character indicating that the code given has one or more additional characters at this location.</td>
</tr>
<tr>
<td>Brackets ([])</td>
<td>In logic definitions</td>
<td>Contains the name of the taxonomy where the associated codes reside.</td>
</tr>
</tbody>
</table>

**Diabetes Group**

- **BLOOD PRESSURE CONTROL**
  - §Controlled BP (less than (<) 140/90 or less than (<) 150/90 if patient is age 60 or older)

**Dental Group**

- **ACCESS TO DENTAL SERVICE**
  - §Dental patients with Dental Exam
  - §All Treatment Completed
  - Pre-natal or Nursing Mother Dental Visit
  - Visits with General Anesthesia
• DENTAL SEALANTS
  – §Dental patients with Dental Sealants

• TOPICAL FLUORIDE
  – §Dental patients with Topical Fluoride
  – Count of Topical Fluoride Applications

• CARIES RISK ASSESSMENT
  – Caries Risk Assessment

Immunizations
• ADULT IMMUNIZATIONS
  – Up-to-date Pneumococcal
  – 1:1 (Tdap/Td, Tdap)
  – 1:1:2 (Tdap/Td, Tdap, 2 Shingrix)
  – 1:1:2:1 (Tdap/Td, Tdap, 2 Shingrix, up-to-date Pneumococcal)
  – §All Age-appropriate Immunizations
  – Up-to-date Pneumococcal for high-risk
  – 2 Shingrix for high-risk
  – Pregnant patients with Tdap
  – Pregnant patients with Influenza
  – Pregnant patients with Tdap and Influenza
  – Pregnant patients with visit and Tdap during 3rd trimester

• CHILDHOOD IMMUNIZATIONS (19 THROUGH 35 MONTHS)
  – 1 Hepatitis A
  – 2 to 3 Rotavirus
  – 2 Influenza

• ADOLESCENT IMMUNIZATIONS
  – 1:1:2* (Tdap/Td, Meningococcal, 2 or 3 HPV)
  – 1:1 (Tdap/Td, Meningococcal)
  – 1 Tdap
  – 1 Meningococcal
  – 2 or 3 HPV

Behavioral Health
• SCREENING, BRIEF INTERVENTION, AND REFERRAL TO TREATMENT
  – +§Brief Negotiated Interview/Brief Intervention (BNI/BI)
• Referral to Treatment

• SUBSTANCE USE DISORDER (SUD) IN WOMEN OF CHILDBEARING AGE
  – SUD Screen
  – Pregnancy Intention Assessment
  – SUD Screen and Pregnancy Intention Assessment
  – Positive Screen for Pregnancy Intention
  – Brief Negotiated Interview/Brief Intervention (BNI/BI)
  – Referral to Treatment

• SUICIDE RISK ASSESSMENT
  – Suicide Risk Assessment

**Cardiovascular Disease-Related**

• WEIGHT ASSESSMENT AND COUNSELING FOR NUTRITION AND PHYSICAL ACTIVITY
  – §Comprehensive Assessment (BMI, Nutrition Counseling, Physical Activity Counseling)
  – BMI Documented
  – Nutrition Counseling
  – Physical Activity Counseling

• PHYSICAL ACTIVITY ASSESSMENT
  – Physical Activity Assessment
  – Exercise Education
  – Exercise Goal

• CARDIOVASCULAR DISEASE AND BLOOD PRESSURE CONTROL
  – BP Documented

• APPROPRIATE MEDICATION THERAPY AFTER A HEART ATTACK
  – Beta-Blocker
  – ASA
  – ACEI/ARB
  – Statin
  – All Meds

**STD Group**

• HUMAN IMMUNODEFICIENCY VIRUS (HIV) SCREENING
- §HIV Screening (no refusals)
- HIV Screening in past five years (no refusals)
- HIV Screening ever for Male User Population aged 25–45
- HIV Diagnosis ever
- First HIV Diagnosis
- §HIV Screens for User Population with no prior HIV diagnosis
- HIV+ with CD4 count

**HIV QUALITY OF CARE**
- CD4 only
- Viral Load only
- Both CD4 and Viral Load
- Any Tests
- Antiretroviral Medication

**HEPATITIS C SCREENING**
- Hepatitis C Screening (Ab Test)
- Positive Ab Result Ever
- Hepatitis C Diagnosis Ever
- Hepatitis C Confirmation Test
- Ever Cured
- Currently Cured
- Hepatitis C Diagnosis ever
- First Hepatitis C Diagnosis

**CHLAMYDIA TESTING**
- Chlamydia Testing
- Chlamydia Test Refusal
- Chlamydia Testing for Patients Identified as Sexually Active (HEDIS)

**SEXUALLY TRANSMITTED INFECTION (STI) SCREENING**
- §Needed HIV Screen
- HIV Screen Refusal

**Other Clinical Measures**

**PROPORTION OF DAYS COVERED BY MEDICATION THERAPY**
- PDC greater than or equal to (≥) 80%
- Gap greater than or equal to (≥) 30 days
− PDC greater than or equal to (≥) 90%

• MEDICATION THERAPY MANAGEMENT SERVICES
  − Medication Therapy Management

• CONCURRENT USE OF OPIOIDS AND BENZODIAZEPINES
  − Concurrent Use of Opioids and Benzodiazepines

• USE OF BENZODIAZEPINE SEDATIVE HYPNOTIC MEDICATIONS IN THE ELDERLY
  − Benzodiazepine Sedative Hypnotic Medications

• OPTOMETRY
  − §Optic Nerve Head Evaluation

**Note:** Definitions for all GPRA Developmental performance measures topics included in CRS begin in Section 2.0.

### 1.1 CRS Denominator Definitions

#### 1.1.1 For All Denominators

- All patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component [PCC] Management Reports, Other section) will be excluded automatically for all denominators.

- For all measures, except as noted, patient age is calculated as of the beginning of the Report Period.

#### 1.1.2 For All Numerators

For all measures, except as noted, GPRA Developmental Numerators do not include refusals or contraindications.

#### 1.1.3 Active Clinical Population

**1.1.3.1 National GPRA/GPRAMA Reporting**

- Must have two visits to medical clinics in the past three years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face to face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2022 Clinical Measures User Manual for listing of these clinics.
- Must be alive on the last day of the Report Period.
- Must be American Indian/Alaska Native (AI/AN); defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Purchased and Referred Care (PRC) catchment area.

1.1.3.2 Local Reports

- Must have two visits to medical clinics in the past three years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face to face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2022 Clinical Measures User Manual for listing of these clinics.
- Must be alive on the last day of the Report Period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.1.4 User Population

1.1.4.1 National GPRA/GPRAMA Reporting

- Must have been seen at least once in the three years prior to the end of the Report Period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report Period.
- Must be AI/AN; defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined PRC catchment area.

1.1.4.2 Local Reports

- Must have been seen at least once in the three years prior to the end of the Report Period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report Period.
• User defines population type: AI/AN patients only, non-AI/AN, or both.
• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.1.5 Active Clinical Plus BH Population

1.1.5.1 National GPRA/GPRAMA Reporting
• Must have two visits to medical or behavioral health clinics in the past three years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face to face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2022 Clinical Measures User Manual for listing of these clinics.
• Must be alive on the last day of the Report Period.
• Must be AI/AN; defined as Beneficiary 01.
• Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Purchased and Referred Care (PRC) catchment area.

1.1.5.2 Local Reports
• Must have two visits to medical or behavioral health clinics in the past three years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face to face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2022 Clinical Measures User Manual for listing of these clinics.
• Must be alive on the last day of the Report Period.
• User defines population type: AI/AN patients only, non-AI/AN, or both.
• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
2.0 Performance Measure Topics and Definitions

The following sections define the performance measure topics and their definitions that are included in the CRS 2022 version 22.1 National GPRA Developmental Report.

2.1 Diabetes Group

2.1.1 Diabetes: Blood Pressure Control

2.1.1.1 Owner and Contact

Diabetes Program: Carmen Hardin

2.1.1.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.1.1.3 Denominators

1. GPRA: Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever or DM entry on the Problem List.

2. Active Diabetic patients under age 60.

3. Active Diabetic patients aged 60 and older.

2.1.1.4 Numerators

1. GPRA Developmental: Patients with controlled blood pressure, defined as less than 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90 or, if patient is 60 and over, with blood pressure less than 150/90, i.e., the mean systolic value is less than (<) 150 and the mean diastolic value is less than (<) 90.

2. Patients with blood pressure less than (<) 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90.

3. Patients with blood pressure less than (<) 150/90, i.e., the mean systolic value is less than (<) 150 and the mean diastolic value is less than (<) 90.
2.1.1.5 Definitions

Diabetes
First DM Purpose of Visit recorded in the V POV file or Problem List Entry with Date of Onset or Date Entered prior to the Report Period:

- ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.*  
  [SURVEILLANCE DIABETES]
- SNOMED data set PXRM DIABETES (Problem List only)

Exclusions
When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded:

- Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation)
  - Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)

BP Documented
CRS uses the mean of the last three BPs documented during the Report Period. If three BPs are not available, CRS uses the mean of the last two BPs, or one BP if there is only one documented. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean diastolic value is calculated by adding the diastolic values from the last three (or two) BPs and dividing by three (or two).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS] documented during the Report Period.

Controlled BP
CRS uses a mean, as described previously where the BP is less than (<) 140/90 or less than (<) 150/90 for patients aged 60 and older. If both the mean systolic and diastolic values do not meet the criteria for controlled, then the value is considered not controlled.

BP Documented and Controlled BP
If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented during the Report Period:

- CPT G9273; or
• Systolic: CPT 3074F, 3075F, or 3077F [BGP SYSTOLIC BP CPTS] WITH Diastolic: CPT 3078F, 3079F, or 3080F [BGP DIASTOLIC BP CPTS]. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.

• The following combinations represent BP less than (<) 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F, OR G9273. All other combinations will not be included in the Controlled BP numerator.

2.1.1.6 Patient Lists

• List of diabetic patients with blood pressure less than (<) 140/90, or less than (<) 150/90 for patients age 60 and older.

• List of diabetic patients with blood pressure greater than or equal to (≥) 140/90, or greater than or equal to (≥) 150/90 for patients age 60 and older.

2.2 Dental Group

2.2.1 Access to Dental Service

2.2.1.1 Owner and Contact

Dental Program: Timothy L. Ricks, DMD, MPH; Nathan P. Mork, DDS, MPH

2.2.1.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.2.1.3 Denominators


3. Pregnant or breastfeeding female User Population patients with no documented miscarriage or abortion.
2.2.1.4 Numerators

1. GPRA Developmental: Patients with dental exam (with Denominator 1).

2. GPRA Developmental: Patients with all treatment completed (with Denominator 2).

3. Patients with documented pre-natal or nursing mother dental visit during the Report Period (with Denominator 3).

**Note:** This numerator does not include refusals.

4. Count only (no percentage comparison to denominator). For patients younger than age 6 years meeting the User Population definition, the total number of encounters with general anesthesia during the Report Period.

2.2.1.5 Definitions

**Documented Dental Visit**

Any of the following:

- IHS Dental Tracking code 0000, 0007, 0190
- RPMS Dental codes 0110 through 0390, 0415 through 0471, 0601 through 0603, 0999 through 9974, 9995, 9996, 9999
- ADA CDT codes D0110 through D0390, D0415 through D9952, D9970 through D9974, D9995, D9996, D9999 [BGP DENTAL VISIT CPT CODES]
- Exam code 30
- POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21, Z13.84, Z29.3 [BGP DENTAL VISIT DXS]

**Dental Exam**

- RPMS Dental codes 0120, 0150, 0145
- ADA CDT D0120, D0150, D0145 [BGP DENTAL EXAM CPTS]

**All Treatment Completed**

- RPMS Dental code 9990

**Pre-natal or Nursing Mother Dental Visit**

- IHS Dental Tracking codes 9340, 9341
Pregnancy

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period.
- At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53) with any of the following:
  - Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
  - CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.

The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to “Yes.”

**Miscarriage**
Occurring after the second pregnancy POV and during the past 20 months
- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion**
Occurring after the second pregnancy POV and during the past 20 months
- POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Breastfeeding**
Any of the following during the Report Period:
- The Lactation Status field in Reproductive Factors file set to “Lactating”
- Diagnosis:
  - POV ICD-9: V24.1; ICD-10: O91.03, O91.13, O91.23, O92.03, O92.13, O92.5, O92.70, O92.79, Z39.1 [BGP ECQM BREASTFEED DXS]
  - SNOMED data set PXRM BGP ECQM BREASTFEED

**General Anesthesia**
- RPMS Dental code 9220 (old code), 9222
• ADA CDT D9220 (old code), D9222 [BGP CPT DENT GEN ANESTHESIA]

2.2.1.6 Patient Lists

• List of User Population patients with dental visit during the Report Period with dental exam.
• List of User Population patients with dental visit during the Report Period with no dental exam.
• List of User Population patients with dental exam and all treatment completed.
• List of User Population patients with dental exam and not all treatment completed.
• List of pregnant or breastfeeding female patients with treatment.
• List of pregnant or breastfeeding female patients without treatment.
• List of User Population patients younger than 6 years of age with general anesthesia.

2.2.2 Dental Sealants

2.2.2.1 Owner and Contact

Dental Program: Timothy L. Ricks, DMD, MPH; Nathan P. Mork, DDS, MPH

2.2.2.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.2.2.3 Denominators

1. GPRA Developmental: User Population patients aged 2–15 years with documented dental visit during the Report Period.

2.2.2.4 Numerators

1. GPRA Developmental: Patients with at least one or more intact dental sealants.
2.2.2.5 Definitions

Documented Dental Visit

Any of the following:

- IHS Dental Tracking code 0000, 0190
- RPMS Dental codes 0110 through 0390, 0415 through 0471, 0601 through 0603, 0999 through 9974, 9995, 9996, 9999
- ADA CDT codes D0110 through D0390, D0415 through D9952, D9970 through D9974, D9995, D9996, D9999 [BGP DENTAL VISIT CPT CODES]
- Exam code 30
- POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21, Z13.84, Z29.3 [BGP DENTAL VISIT DXS]

Intact Dental Sealant

- Any of the following documented during the Report Period:
  - RPMS Dental codes 1351, 1352, 1353
  - ADA CDT D1351, D1352, D1353
- Or any of the following documented during the past three years from the end of the Report Period:
  - IHS Dental Tracking code 0007

If both RPMS Dental and ADA CDT codes are found on the same visit, only the RPMS Dental code will be counted. IHS Dental Tracking code 0007 will be counted regardless of whether another sealant code is submitted on the same visit or date of service.

2.2.2.6 Patient Lists

- List of User Population patients aged 2–15 years with dental visit during the Report Period with intact dental sealant.
- List of User Population patients aged 2–15 years with dental visit during the Report Period without intact dental sealant.

2.2.3 Topical Fluoride

2.2.3.1 Owner and Contact

Dental Program: Timothy L. Ricks, DMD, MPH; Nathan P. Mork, DDS, MPH
2.2.3.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.2.3.3 Denominators


2.2.3.4 Numerators

1. GPRA Developmental: Patients who received one or more topical fluoride applications during the Report Period.

2. Count only: For patients meeting the User Population definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

2.2.3.5 Definitions

Documented Dental Visit

Any of the following:

- IHS Dental Tracking code 0000, 0190
- RPMS Dental codes 0110 through 0390, 0415 through 0471, 0601 through 0603, 0999 through 9974, 9995, 9996, 9999
- ADA CDT codes D0110 through D0390, D0415 through D9952, D9970 through D9974, D9995, D9996, D9999 [BGP DENTAL VISIT CPT CODES]
- Exam code 30
- POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21, Z13.84, Z29.3 [BGP DENTAL VISIT DXS]

Topical Fluoride Application

Defined as any of the following:

- RPMS Dental codes 1201 (old code), 1203 (old code), 1204 (old code), 1205 (old code), 1206, 1208, 5986
- ADA CDT D1201 (old code), D1203 (old code), D1204 (old code), D1205 (old code), D1206, D1208, D5986, 99188 [BGP CPT TOPICAL FLUORIDE]
- POV ICD-9: V07.31; ICD-10: Z29.3 [BGP TOPICAL FLUORIDE DXS]
A maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

2.2.3.6 Patient Lists

- List of User Population patients aged 1–15 years with dental visit during the Report Period with topical fluoride application.
- List of User Population patients aged 1–15 years with dental visit during the Report Period without topical fluoride application.
- List of patients who received at least one topical fluoride application during Report Period.

2.2.4 Caries Risk Assessment

2.2.4.1 Owner and Contact
Dental Program: Timothy L. Ricks, DMD, MPH; Nathan P. Mork, DDS, MPH

2.2.4.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.2.4.3 Denominators
1. User Population patients with a dental exam. Broken down by age groups: 0 through 2, 3 through 5, 6 through 9, 10 through 12, 13 through 15, 16 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 64, 65 through 74, and 75 and older

2.2.4.4 Numerators
1. Patients with a caries risk assessment.

2.2.4.5 Definitions
Dental Exam
- RPMS Dental codes 0120, 0150, 0145
- ADA CDT D0120, D0150, D0145 [BGP DENTAL EXAM CPTS]

Caries Risk Assessment
- RPMS Dental codes 0601, 0602, 0603
• ADA CDT D0601, D0602, D0603

2.2.4.6 Patient Lists

• List of User Population patients with dental exam during the Report Period with caries risk assessment.
• List of User Population patients with dental exam during the Report Period without caries risk assessment.

2.3 Immunization Group

2.3.1 Adult Immunizations

2.3.1.1 Owner and Contact
National Immunization Program: Uzo Chukwuma, MPH

2.3.1.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.3.1.3 Denominators
1. User Population Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever or DM entry on the Problem List.
4. User Population patients aged 66 years and older.
5. User Population patients aged 19 years and older.
6. User Population patients ages 19 and older with cerebrospinal fluid leak or cochlear implant.
7. User Population patients ages 19 and older with immunocompromising condition.
8. User Population patients ages 19 and older with other underlying medical condition or risk factor.
10. Pregnant female Active Clinical patients with no documented miscarriage or abortion.

11. Pregnant female Active Clinical patients with no documented miscarriage or abortion who had a visit during the third trimester.

### 2.3.1.4 Numerators

**Note:** The only refusals included in all numerators are documented NMI refusals.

1. Patients with up-to-date Pneumococcal vaccine (with Denominators 1 and 8).

2. Patients who have received the 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever), including contraindications (with Denominator 2).

3. Patients who have received the 1:1:2 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever), including contraindications (with Denominator 3).

4. Patients who have received the 1:1:2:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever, 1 up-to-date Pneumococcal vaccine), including contraindications (with Denominator 4).

5. Patients who have received all age-appropriate immunization combinations (with Denominator 5).

6. Patients with high-risk up-to-date Pneumococcal vaccine (with Denominators 6 and 7).

7. Patients who have received 2 doses of Shingrix ever, including contraindications (with Denominator 9).

8. Patients who have received 1 dose of Tdap in the past 20 months, including contraindications (with Denominator 10).
   
   A. Patients with a contraindication or a documented NMI (not medically indicated) refusal.
   
   B. Patients with Tdap during the first trimester.
   
   C. Patients with Tdap during the second trimester.
   
   D. Patients with Tdap during the third trimester.
   
   E. Patients with Tdap during unknown trimester.
9. Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period (with Denominator 10).

   A. Patients with a contraindication or a documented NMI (not medically indicated) refusal.

10. Patients who have received 1 dose of Tdap in the past 20 months and an influenza vaccine documented during the Report Period, including contraindications (with Denominator 10).

11. Patients with Tdap during the third trimester (with Denominator 11).

2.3.1.5 Definitions

Diabetes
First DM Purpose of Visit recorded in the V POV file or Problem List Entry with Date of Onset or Date Entered prior to the Report Period:

- ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.*
  [SURVEILLANCE DIABETES]
- SNOMED data set PXRM DIABETES (Problem List only)

Persons Considered High Risk for Pneumococcal
Those who have two or more visits in the past three years with a POV or Problem diagnosis of any of the following:

Cerebrospinal fluid leak or cochlear implant:
- Cerebrospinal fluid leak: ICD-9: 349.81, 388.61; ICD-10 G96.0
- Cochlear implant: ICD-9: V45.89; ICD-10 Z96.21

Immunocompromising condition:
- HIV Infection: ICD-9: 042, 042.0 through 043.9 (old codes), 044.9 (old code), 079.53, V08; ICD-10: B20, B52, B97.35, Z21
- Nephrotic Syndrome: ICD-9: 581.0 through 581.9; ICD-10: N02.*, N04.*, N08
- Renal Failure: ICD-9: 585.6, 585.9; ICD-10: N18.6 through N19
- Transplant: ICD-9: 996.80 through 996.89; ICD-10: T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
- Kidney Transplant: ICD-9: V42.0 through V42.89
- Chemotherapy: ICD-9: V58.1; ICD-10: Z51.11, Z51.12
• Chemotherapy Follow-up: ICD-9: V67.2; ICD-10: Z08
• Sickle cell disease/other hemoglobinopathy: ICD-9: 282.0, 282.1, 282.4*, 282.6*, 282.7; ICD-10 D56.0 through D58.90
• Congenital or acquired asplenia: ICD-9: 289.59, 759.0, V45.79; ICD-10 Q89.01, Q89.09, D73.5, Z90.81
• Congenital or acquired immunodeficiency: ICD-9: 279.*; ICD-10 D80.*, D81.0 through D81.7, D81.89, D81.9, D82.* through D84.*, D89.3, D89.8*, D89.9
• Leukemia, Lymphoma, Multiple myeloma: ICD-9: 200.00 through 208.92; ICD-10: C81.00 through C86.6, C88.2 through C88.9, C90.00 through C93.*, C94.00 through C94.32, C94.80, C95.*, C96.0 through C96.4, C96.9, C96.A, C96.Z
• Hodgkin disease: ICD-10: C81.*, Z85.71
• Generalized malignancy: ICD-9: 140.* through 172.*, 174.* through 209.3*, 209.7*, 235.* through 239.*; ICD-10: C00.* through C80.*, C4A.*

Other underlying medical condition or risk factor:
• Diabetes: ICD-9: 250.00 through 250.93; ICD-10: E08.2*, E09.2*, E10.* through E13.*
• Chronic Alcoholism: ICD-9: 303.90, 303.91; ICD-10: F10.20, F10.220 through F10.29
• Congestive Heart Failure and Cardiomyopathies: ICD-9: 428.0 through 428.9, 429.2; ICD-10: B33.24, I09.0, I25.5, I42.*, I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9, I51.7
• Emphysema: ICD-9: 492.0 through 492.8; ICD-10: J43.*
• Asthma: ICD-9: 493.00 through 493.91; ICD-10: J45.21 through J45.902
• Bronchiectasis, CLD, COPD: ICD-9: 494. through 496.; ICD-10: J44.*, J47.*
• Pneumoconiosis: ICD-9: 501. through 505.; ICD-10: J60 through J64, J66.8 through J67.6, J67.8 through J67.9
• Chronic Liver Disease: ICD-9: 571.0 through 571.9; ICD-10: K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
• Cigarette smoking:
  – Health Factors: Current Smoker and Smokeless [F030]; Current Smoker, status unknown [F002]; Current smoker, every day [F108]; Current smoker, some day [F109]; Heavy Tobacco Smoker [F121]; Light Tobacco Smoker [F122]
Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10 through 305.12 (old codes), 649.00 through 649.04; ICD-10: F17.200, F17.203 through F17.210, F17.213 through F17.219, F17.290, F17.293 through F17.299, O99.33*; SNOMED data set PXRM BGP TOBACCO SMOKER (Problem List only)

CPT 99406, 99407, G0375 (old code), G0376 (old code), G8455 (old code), G8402 (old code), G8453 (old code), G9016, or 1034F

Persons Considered High Risk for Zoster

Those who have two or more visits in the past three years with a POV or Problem diagnosis of any of the following:

- Bone Marrow Transplant: ICD10: Z94.81
- Leukemia, Lymphoma, Hodgkin lymphoma. Multiple myeloma: ICD-9: 200.00-208.92; ICD-10: C81.00-C86.6, C88.2-C88.9, C90.00-C93.0, C94.00-C94.32, C94.80, C95.9, C96.0-C96.4, C96.9, C96.A, C96.Z, Z85.71
- Transplant: ICD-9: 996.80-996.89; ICD-10: T86.00-T86.819, T86.83*, T86.850-T86.899, Z48.21-Z48.280, Z48.290, Z94.0-Z94.4, Z94.6, Z94.81-Z94.84, Z95.3, Z95.4
- Kidney Transplant: ICD-9: V42.0-V42.89
- Generalized malignancy: ICD-9: 140.* through 172.*, 174.* through 209.3*, 209.7*, 235.* through 239.*; ICD-10: C00.* through C00.9, C4A.*
- HIV Infection: ICD-9: 042, 042.0-043.9 (old codes), 044.9 (old code), 079.53, V08; ICD-10: B20, B97.35, Z21
- Congenital or acquired immunodeficiency: ICD-9: 279.*; ICD-10: D80.*, D81.0-D81.7, D81.89, D81.9, D82.-D84.*, D89.3, D89.8*, D89.9
- Poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drugs: ICD10: T45.1X*
- Personal history of immunosuppression therapy: ICD10: Z92.25
- Congenital or acquired asplenia: ICD-9: 289.59, 759.0, V45.79; ICD-10 Q89.01, Q89.09, D73.5, Z90.81

Pregnancy

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period
- At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53) with any of the following:

- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

- CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.
The patient must not have a documented miscarriage or abortion occurring after
the second pregnancy-related visit or the date the Currently Pregnant field was set
to “Yes.”

Miscarriage
- Occurring after the second pregnancy POV and during the past 20 months
  - POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

Abortion
- Occurring after the second pregnancy POV and during the past 20 months
  - POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

Age-appropriate Immunization Combinations
- Ages 19–50: 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever)
- Ages 51–65: 1:1:2 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever)
- Ages 66 and older: 1:1:2:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever, 1 up-to-date Pneumococcal vaccine)

Up-to-date Pneumococcal vaccine (PCV20, PCV15, PPSV23, PCV13) is
defined as any of the following:
- Patients who have ever received PCV20.
- Patients who have received PCV15 followed by PPSV23 at least eight weeks apart.
- Patients who have received PPSV23 followed by PCV15 or PCV20 at least one year apart.
- Patients who have received PCV13 at any age followed by PPSV23 at age 65 years or older at least one year apart.
• Patients with a contraindication to Pneumococcal Conjugate (PCV20, PCV15, or PCV13) and a PPSV23 vaccine or contraindication at any time.

**High-risk up-to-date Pneumococcal vaccine (PCV20, PCV15, PPSV23, PCV13)** is defined as any of the following:

• Patients who have ever received PCV20.
• Patients who have received PCV15 followed by PPSV23 at least eight weeks apart.
• Patients who have received PPSV23 followed by PCV15 or PCV20 at least one year apart.
• Patients with a contraindication to Pneumococcal Conjugate (PCV20, PCV15, or PCV13) and a PPSV23 vaccine or contraindication at any time.
• For patients with cerebrospinal fluid leak or cochlear implant:
  – Patients who have received PCV13 followed by PPSV23 at least eight weeks apart, and if patient is older than 65, an additional dose of PPSV23 at least five years after the first dose of PPSV23.

**Note:** If patient is older than 65 when the first dose of PPSV23 is given, they do not need a second dose of PPSV23.

• For patients with immunocompromising condition:
  – Patients under age 65: Must receive PCV13 followed by PPSV23 at least eight weeks apart, followed by a second dose of PPSV23 at least five years apart.
  – Patients over age 65: Must receive PCV13 followed by PPSV23 at least eight weeks apart, and if patient was less than 65 at time of most recent PPSV23, then a dose of PPSV23 after age 65 and at least five years after last dose.

**Note:** Patients 65 and older should only receive one dose of PPSV23 at age 65 years or older. All patients should receive no more than 3 doses of PPSV23.

**High-Risk PCV13/PPSV23 Examples:**

Patients with cerebrospinal fluid leak or cochlear implant:

• Patient #1:
  – PCV13 at age 20 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  – PPSV23 at age 21 (is now up-to-date until age 65)
- PPSV23 at age 65 (is up-to-date)
- Patient #2:
  - PCV13 at age 63 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  - PPSV23 at age 63, 8 weeks after PCV13 (is up-to-date until age 68, 5 years after PPSV23)
  - PPSV23 at age 69 (is now up-to-date)
- Patient #3:
  - PCV13 at age 64 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  - PPSV23 at age 65 (is now up-to-date)
  - Does not need final PPSV23 dose

Patients with immunocompromising condition:
- Patient #1:
  - PCV13 at age 20 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  - PPSV23 at age 21 (is now up-to-date until age 26, 5 years after first PPSV23)
  - PPSV23 at age 30 (is now up-to-date until age 65)
  - PPSV23 at age 65 (is up-to-date)
- Patient #2:
  - PCV13 at age 63 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  - PPSV23 at age 63, 8 weeks after PCV13 (is up-to-date until age 68, 5 years after PPSV23)
  - PPSV23 at age 69 (is now up-to-date)
  - Does not need final PPSV23 dose
- Patient #3:
  - PCV13 at age 64 (is up-to-date for 8 weeks [56 days], after which is not up-to-date until PPSV23 is received)
  - PPSV23 at age 65 (is now up-to-date)
  - Does not need final two PPSV23 doses
Tdap Immunization:
Any of the following documented during the applicable time frame. For pregnant patients, the Tdap must have occurred in the past 20 months and must be on or after a pregnancy visit:

- Immunization (CVX) code: 115
- CPT 90715

Tdap Contraindication
Any of the following documented any time before the end of the Report Period:

- Immunization Package contraindication of “Anaphylaxis”
- PCC NMI Refusal

Td Immunization
Any of the following documented in the past 10 years:

- Immunization (CVX) code 9, 113, 138, 139, 196
- POV ICD-9: V06.5 [BGP TD IZ DXS]
- CPT 90714, 90718 [BGP CPT TDAP/TD]

Td Contraindication
Any of the following documented any time before the end of the Report Period:

- Immunization Package contraindication of “Anaphylaxis”
- PCC NMI Refusal

Shingrix Vaccine
Any of the following documented ever (the two doses must be at least two months apart):

- Immunization (CVX) codes 187
- CPT 90750 [BGP ZOSTER SHINGRIX CPTS]

Contraindication to Shingrix Vaccine
Any of the following documented at any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Immune Deficiency” or “Anaphylaxis”
- PCC NMI Refusal
Influenza Vaccine
Any of the following during the Report Period:

- Immunization (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186, 194, 197, 200-202, 205
- POV ICD-9: V04.8 (old code), V04.81 [BGP FLU IZ DX V04.8]
- CPT 90630, 90653 through 90662, 90672 through 90674, 90682, 90685 through 90689, 90724 (old code), 90756, G0008, G8108 (old code), Q2034 through Q2039 [BGP CPT FLU]

Contraindication to Influenza Vaccine
Any of the following documented at any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Anaphylaxis”
- PCC NMI Refusal

Pneumococcal Polysaccharide (PPSV23) Vaccine
Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 33, 109
- POV ICD-9: V03.82 [BGP PNEUMO IZ DXS]
- CPT 90732, G0009, G8115 (old code), G9279 [BGP PNEUMO IZ CPT DEV]

Pneumococcal Polysaccharide Contraindication
Any of the following documented:

- Contraindication in the Immunization Package of “Anaphylaxis” any time before the end of the Report Period
- PCC NMI Refusal any time before the end of the Report Period

Pneumococcal Conjugate (PCV13)
Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 100, 133, 152
- CPT 90669, 90670 [BGP PNEUMO CONJUGATE CPTS]

Pneumococcal Conjugate (PCV20)
Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 216
- CPT 90677
Pneumococcal Conjugate (PCV15)

Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 215
- CPT 90671

Pneumococcal Conjugate Contraindication

Any of the following documented:

- Contraindication in the Immunization Package of “Anaphylaxis” any time before the end of the Report Period
- PCC NMI Refusal any time before the end of the Report Period

Trimesters

Trimesters will be calculated based on the patient’s due date, assuming a 40-week pregnancy, or by the trimester specified in an ICD-10 POV code. For the purposes of these measures, trimesters are defined as: (1) 1st Trimester = 0–13 weeks, (2) 2nd Trimester = 14–26 weeks, (3) 3rd Trimester = 27–40 weeks.

CRS will determine the trimester (if possible) in the following order:

1) Look at the Current Definitive EDD field in the BJPN PRENATAL PROBLEMS file for a date during the Report Period or up to eight months after the Report Period.
2) Look at the Definitive EDD field in the Reproductive Factors file for a date during the Report Period or up to eight months after the Report Period.
3) Look for an Estimated Gestational Age (EGA) in the V Measurement file that was entered in the past 20 months. The due date will be calculated using the following formula:

$$\text{Due Date} = 40 \text{ weeks} - \text{EGA (in weeks)} + \text{Date EGA was entered}$$

The calculated due date must be after the beginning of the Report Period.

4) Look for an ICD-10 POV code that specifies trimester. The POV code must be within seven days of the Tdap date of visit.

A) First Trimester: POV ICD-10: 009.01, 009.11, 009.211, 009.291, 009.31, 009.41, 009.511, 009.521, 009.611, 009.621, 009.71, 009.811, 009.821, 009.891, 009.91, 010.011, 010.111, 010.211, 010.311, 010.411, 010.911, 011.1, 012.01, 012.11, 012.21, 013.1, 016.1, 022.01, 022.11, 022.21, 022.31, 022.41, 022.51, 022.8X1, 022.91, 023.01, 023.11, 023.21, 023.31, 023.41, 023.511, 023.521, 023.591, 023.91, 024.011, 024.111, 024.311, 024.811, 024.911, 025.11, 026.01, 026.11, 026.21, 026.31, 026.41, 026.51, 026.611, 026.711, 026.811, 026.821, 026.831, 026.841, 026.851, 026.891, 026.91, 029.011, 029.021, 029.091, 029.111, 029.121, 029.191, 029.211, 029.291,
O29.3X1, O29.41, O29.5X1, O29.61, O29.8X1, O29.91, O30.001, O30.011, O30.021, O30.031, O30.041, O30.091, O30.101, O30.111, O30.121, O30.191, O30.201, O30.211, O30.221, O30.291, O30.801, O30.811, O30.821, O30.891, O31.01X0, O31.01X1, O31.01X2, O31.01X3, O31.01X4, O31.01X5, O31.01X9, O31.11X0, O31.11X1, O31.11X2, O31.11X3, O31.11X4, O31.11X5, O31.11X9, O31.21X0, O31.21X1, O31.21X2, O31.21X3, O31.21X4, O31.21X5, O31.21X9, O31.31X0, O31.31X1, O31.31X2, O31.31X3, O31.31X4, O31.31X5, O31.31X9, O31.8X10, O31.8X11, O31.8X12, O31.8X13, O31.8X14, O31.8X15, O31.8X19, O34.01, O34.11, O34.31, O34.41, O34.511, O34.521, O34.531, O34.591, O34.61, O34.71, O34.81, O34.91, O35.011, O35.011, O35.011, O35.011, O35.091, O35.091, O35.091, O35.091, O35.091, O35.091, O35.091, O35.091, O35.091, O35.11X0, O35.11X1, O35.11X2, O35.11X3, O35.11X4, O35.11X5, O35.11X9, O35.12X0, O35.12X1, O35.12X2, O35.12X3, O35.12X4, O35.12X5, O35.12X9, O35.19X0, O35.19X1, O35.19X2, O35.19X3, O35.19X4, O35.19X5, O35.19X9, O36.0110, O36.0111, O36.0112, O36.0113, O36.0114, O36.0115, O36.0119, O36.0910, O36.0911, O36.0912, O36.0913, O36.0914, O36.0915, O36.0919, O36.1110, O36.1111, O36.1112, O36.1113, O36.1114, O36.1115, O36.1119, O36.1910, O36.1911, O36.1912, O36.1913, O36.1914, O36.1915, O36.1919, O36.21X0, O36.21X1, O36.21X2, O36.21X3, O36.21X4, O36.21X5, O36.21X9, O36.5110, O36.5111, O36.5112, O36.5113, O36.5114, O36.5115, O36.5119, O36.5910, O36.5911, O36.5912, O36.5913, O36.5914, O36.5915, O36.5919, O36.61X0, O36.61X1, O36.61X2, O36.61X3, O36.61X4, O36.61X5, O36.61X9, O36.71X0, O36.71X1, O36.71X2, O36.71X3, O36.71X4, O36.71X5, O36.71X9, O36.8210, O36.8211, O36.8212, O36.8213, O36.8214, O36.8215, O36.8219, O36.8910, O36.8911, O36.8912, O36.8913, O36.8914, O36.8915, O36.8919, O36.91X0, O36.91X1, O36.91X2, O36.91X3, O36.91X4, O36.91X5, O36.91X9, O40.1XX0, O40.1XX1, O40.1XX2, O40.1XX3, O40.1XX4, O40.1XX5, O40.1XX9, O40.01X0, O40.01X1, O40.01X2, O40.01X3, O40.01X4, O40.01X5, O40.01X9, O40.1011, O40.1012, O40.1013, O40.1014, O40.1015, O40.1019, O40.1210, O40.1211, O40.1212, O40.1213, O40.1214, O40.1215, O40.1219, O40.1410, O40.1411, O40.1412, O40.1413, O40.1414, O40.1415, O40.1419, O40.18X10, O40.18X11, O40.18X12, O40.18X13, O40.18X14, O40.18X15, O40.18X19, O40.19X0, O40.19X1, O40.19X2, O40.19X3, O40.19X4, O40.19X5, O40.19X9, O42.011, O42.111, O42.911, O43.011, O43.021, O43.101, O43.111, O43.121, O43.191, O43.211, O43.221, O43.231, O43.811, O43.911, O44.01, O44.11, O44.11, O45.001, O45.011, O45.021, O45.091, O45.8X1, O45.91, O46.001, O46.011, O46.021, O46.091, O46.8X1, O46.91, O88.011, O88.111, O88.211, O88.311, O88.811, O91.011, O91.111, O91.211, O92.011, O98.011, O98.111, O98.211, O98.311, O98.411, O98.511, O98.611, O98.711, O98.811, O99.011, O99.111, O99.211, O99.281, O99.311, O99.321, O99.331, O99.341, O99.351, O99.411, O99.511, O99.611, O99.711, O99.841, O9A.111, O9A.211, O9A.311, O9A.411, O9A.511, Z3A.08, Z3A.09, Z3A.10, Z3A.11, Z3A.12, Z3A.13, Z3A.14, Z3A.15, Z3A.16, [BGP PREGNANCY TRI 1 DXS]

**B) Second Trimester:** POV ICD-10: 009.02, 009.12, 009.212, 009.292, 009.32, 009.42, 009.512, 009.522, 009.612, 009.622, 009.72, 009.812, 009.822, 009.892, 009.92, 010.012, 010.112, 010.212, 010.312, 010.412, 010.912, 011.2, 012.02, 012.12, 012.22, 013.2, 014.02, 014.12, 014.22,
<table>
<thead>
<tr>
<th>Performance Measure List and Definitions</th>
<th>Performance Measure Topics and Definitions</th>
</tr>
</thead>
</table>
O9A.412, O9A.512, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
Z3A.3, Z3A.4, Z3A.5, Z3A.6, Z3A.7, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12,
Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19,
Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28,
2.3.1.6 Patient Lists

- List of diabetic patients with PPSV23 vaccination, contraindication, or NMI refusal.
- List of diabetic patients without PPSV23 vaccination, contraindication, or NMI refusal.
- List of patients aged 19–49 years with 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever).
- List of patients aged 19–49 years without 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever).
- List of patients aged 50–64 years with 1:1:2 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever).
- List of patients aged 50–64 years without 1:1:2 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever).
- List of patients 65+ years with 1:1:2:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever, 1 up-to-date PPSV23).
- List of patients 65+ years without 1:1:2:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 2 doses of Shingrix ever, 1 up-to-date PPSV23).
- List of User Population patients aged 19 years and older with age-appropriate immunizations.
- List of User Population patients aged 19 years and older without age-appropriate immunizations.
- List of pregnant AC patients with Tdap documented in the past 20 months.
- List of pregnant AC patients without Tdap documented in the past 20 months.
• List of pregnant AC patients with Influenza documented during the Report Period.
• List of pregnant AC patients without Influenza documented during the Report Period.
• List of pregnant AC patients with Tdap documented in the past 20 months and Influenza documented during the Report Period.
• List of pregnant AC patients without Tdap documented in the past 20 months and Influenza documented during the Report Period.
• List of pregnant AC patients with a visit during the third trimester with Tdap documented during the third trimester.
• List of pregnant AC patients with a visit during the third trimester without Tdap documented during the third trimester.

2.3.2 Childhood Immunizations

2.3.2.1 Owner and Contact
National Immunization Program: Uzo Chukwuma, MPH

2.3.2.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.3.2.3 Denominators
1. Active Clinical patients aged 19–35 months at end of Report Period.
2. GPRA Developmental: User Population patients active in the Immunization Package who are aged 19–35 months at end of Report Period.

Note: Only values for the Report Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

2.3.2.4 Numerators
1. Patients who have received 1 dose of Hepatitis A vaccine ever, including contraindications and evidence of disease.

Note: The only refusals included in this numerator are NMI refusals.
2. Patients who have received 2 or 3 doses of Rotavirus vaccine ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

3. Patients who have received 2 doses of Influenza ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

### 2.3.2.5 Definitions

#### Patient Age

Since the age of the patient is calculated at the beginning of the Report Period, the age range will be adjusted to 7–23 months at the beginning of the Report Period, which makes the patient between the ages of 19–35 months at the end of the Report Period.

#### Timing of Doses

Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

#### Active Immunization Package Patients Denominator

Same as User Population definition except includes only patients flagged as active in the Immunization Package.

**Note:** Only values for the current period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the previous year or baseline periods.

#### Dosage and Types of Immunizations

- 1 dose of Hep A
- 2 or 3 doses of Rotavirus, depending on the vaccine administered
- 2 doses of Influenza

#### Refusal, Contraindication, and Evidence of Disease Information

Except for the Immunization Program Numerators, NMI refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only.
Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g., 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all the patient’s vaccinations must be part of the smaller-dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all 2 doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator.

- For immunizations where the required number of doses is more than 1, only 1 NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for influenza, the patient will be included in the numerator.

- For immunizations where the required number of doses is more than 1, only 1 contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for influenza, the patient will be included in the numerator.

- Evidence of disease will be checked for at any time in the child’s life (prior to the end of the Report Period).

**NMI Refusal Definitions**

Parent or Patient Refusal in Immunization package or PCC Refusal type REF or NMI for any of the following codes:

- **Hepatitis A**
  - Immunization (CVX) codes 31, 52, 83, 84, 85, 104, 193
  - CPT 90632 through 90634, 90636, 90730 (old code) [BGP HEPATITIS A CPTS]

- **Rotavirus**
  - Immunization (CVX) codes 74, 116, 119, 122
  - CPT 90680

- **Influenza**
  - Immunization (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186, 194, 197, 200-202, 205
  - CPT 90630, 90653 through 90658, 90730 (old code), 90660 through 90662, 90672 through 90674, 90682, 90685 through 90688, 90694, 90724 (old code), 90756, G0008, G8108 (old code), Q2034 through Q2039 [BGP CPT FLU]
**Contraindication Definitions**

- Immunodeficiency
  
  POV or Problem List entry where the status is not Deleted:
  
  - ICD-9: 279.*; ICD-10: D80.*, D81.0 through D81.7, D81.89, D81.9, D82.* through D84.*, D89.3, D89.8*, D89.9 [BGP IMMUNODEFICIENCY DXS]
  
  - SNOMED data set PXRM BGP IPC IMMUNE DIS

- HIV
  
  POV or Problem List entry where the status is not Deleted:
  
  - ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
  
  - SNOMED data set PXRM BGP IPC HIV (Problem List only)

- Lymphoreticular cancer, multiple myeloma, or leukemia
  
  POV or Problem List entry where the status is not Deleted:
  
  - ICD-9: 200.00 through 208.92; ICD-10: C81.00 through C86.6, C88.2 through C88.9, C90.00 through C93.*, C94.00 through C94.32, C94.80, C95.*, C96.0 through C96.4, C96.9, C96.A, C96.Z [BGP LYMPHO CANCER DXS]
  
  - SNOMED data set PXRM BGP IPC LYMPH CANCER

- Severe combined immunodeficiency
  
  POV or Problem List entry where the status is not Deleted:
  
  - ICD-9: 279.2; ICD-10: D81.0 through D81.2, D81.31, D81.9 [BGP SCID DXS]
  
  - SNOMED data set PXRM BGP IPC SCID

- History of intussusception
  
  POV or Problem List entry where the status is not Deleted:
  
  - ICD-9: 560.0; ICD-10: K56.1 [BGP INGUSSUSCEPTION DXS]
  
  - SNOMED data set PXRM BGP IPC INGUSSUS

**Immunization Definitions**

**Note:** In the definitions for all immunizations shown below, the Immunization Program Numerators will include only CVX and CPT codes.

- Hepatitis A Definitions
- Immunization (CVX) codes 31, 52, 83, 84, 85, 104, 193
- CPT 90632 through 90634, 90636, 90730 (old code) [BGP HEPATITIS A CPTS]

- Hepatitis A Evidence of Disease Definitions
  - POV or PCC Problem List (active or inactive) ICD-9: 070.0, 070.1; ICD-10: B15.* [BGP HEPATITIS A EVIDENCE]
  - SNOMED data set PXRM BGP IPC HEP A EVID (Problem List only)

- Hepatitis A Contraindication Definition
  - Immunization Package contraindication of “Anaphylaxis”

- Rotavirus Definitions
  - 2-dose series
    - Immunization (CVX) codes 119
    - CPT 90681
  - 3-dose series
    - Immunization (CVX) codes 74, 116, 122
    - POV ICD-9: V05.8
    - CPT 90680

- Rotavirus Contraindication Definition
  - Immunization Package contraindication of “Anaphylaxis” or “Immune Deficiency”
  - Severe combined immunodeficiency
  - History of intussusception

- Influenza Definitions
  - Immunizations (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186, 194, 197, 200-202, 205
  - POV ICD-9: V04.8 (old code), V04.81 [BGP FLU IZ DXS]
  - CPT 90630, 90653 through 90658, 90659 (old code), 90660 through 90662, 90672 through 90674, 90682, 90685 through 90689, 90694, 90724 (old code), 90756, G0008, G8108 (old code), Q2034 through Q2039 [BGP CPT FLU]

- Influenza Contraindication Definition
  - Immunization Package contraindication of “Anaphylaxis”
  - Immunodeficiency
  - HIV
2.3.2.6 Patient Lists

Note: Because age is calculated at the beginning of the Report Period, the patient’s age on the list will be between 7 and 23 months.

- List of Active Immunization Package patients aged 19–35 months who received 1 dose of the Hep A vaccine.
- List of Active Immunization Package patients aged 19–35 months who have not received 1 dose of the Hep A vaccine.
- List of Active Immunization Package patients aged 19–35 months who received 2 or 3 doses of the rotavirus vaccine.
- List of Active Immunization Package patients aged 19–35 months who have not received 2 or 3 doses of the rotavirus vaccine.
- List of Active Immunization Package patients aged 19–35 months who received 2 doses of the influenza vaccine.
- List of Active Immunization Package patients aged 19–35 months who have not received 2 doses of the influenza vaccine.
- List of Active Immunization Package patients aged 19–35 months who received the 4:3:1:3*:3:1:3 combination (4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hep B, 1 Varicella, and 3 Pneumococcal).
- List of Active Immunization Package patients aged 19–35 months who have not received the 4:3:1:3*:3:1:3 combination (4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hep B, 1 Varicella, and 3 Pneumococcal). If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

2.3.3 Adolescent Immunizations

2.3.3.1 Owner and Contact
National Immunization Program: Uzo Chukwuma, MPH

2.3.3.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)
2.3.3.3 Denominators

1. User Population patients aged 13–17 years.
3. Female User Population patients aged 13–17 years.

2.3.3.4 Numerators

1. Patients who have received the 1:1:2* combination (i.e., 1 Tdap or Td, 1 Meningococcal, 2 or 3 HPV), including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

2. Patients who have received the 1:1 combination (i.e., 1 Tdap or Td, 1 Meningococcal), including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

3. Patients who have received 1 dose of Tdap ever, including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

4. Patients who have received 1 dose of meningococcal ever, including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

5. Patients who have received 2 or 3 doses of HPV ever, including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

2.3.3.5 Definitions

Timing of Doses

Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.
Dosage and Types of Immunizations

- 1 dose of Td or Tdap
- 1 dose of Meningococcal
- 2 or 3 doses of HPV – to qualify for two doses, the patient must have the first dose prior to their 15th birthday, and the two doses must be separated by a minimum of five months.

Not Medically Indicated Refusal, Contraindication, and Evidence of Disease Information

NMI refusals and contraindications for individual immunizations will also count toward meeting the definition, as defined in the following section.

Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations where the required number of doses is greater than one, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for HPV, the patient will be included in the numerator.

- For immunizations where required number of doses is greater than one, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HPV, the patient will be included in the numerator.

NMI Refusal Definitions

PCC Refusal type NMI for any of the following codes:

- Tdap
  - Immunization (CVX) codes 115
  - CPT 90715

- Td
  - Immunization (CVX) codes 9, 113, 138, 139, 196
  - CPT 90714, 90718

- Meningococcal
  - CPT 90619, 90644, 90733, 90734

- HPV
  - Immunization (CVX) codes 62, 118, 137, 165
  - CPT 90649, 90650, 90651
Immunization Definitions

- **Tdap**
  - Immunization (CVX) code 115
  - CPT 90715
- **Tdap Contraindication**
  - Immunization Package contraindication of “Anaphylaxis”
- **Td**
  - Immunization (CVX) code 9, 113, 138, 139, 196
  - POV ICD-9: V06.5 [BGP TD IZ DXS]
  - CPT 90714, 90718
- **Td Contraindication**
  - Immunization Package contraindication of “Anaphylaxis”
- **Meningococcal**
  - CPT 90619, 90644, 90733, 90734
- **Meningococcal Contraindication**
  - Immunization Package contraindication of “Anaphylaxis”
- **HPV**
  - Immunization (CVX) codes 62, 118, 137, 165
  - CPT 90649, 90650, 90651
- **HPV Contraindication**
  - Immunization Package contraindication of “Anaphylaxis”

### 2.3.3.6 Patient Lists

- List of User Population patients aged 13–17 years with 1:1:2* combination (i.e., 1 Tdap or Td, 1 Meningococcal, 2 or 3 HPV).
- List of User Population patients aged 13–17 years without 1:1:2* combination (i.e., 1 Tdap or Td, 1 Meningococcal, 2 or 3 HPV). If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 1 HPV, no IZ will be listed for HPV.
- List of User Population patients aged 13–17 years with 1:1 combination (i.e., 1 Tdap or Td, 1 Meningococcal).
- List of User Population patients aged 13–17 years without 1:1 combination (i.e., 1 Tdap or Td, 1 Meningococcal).
• List of User Population patients aged 13–17 years with 1 Tdap ever.
• List of User Population patients aged 13–17 years without 1 Tdap ever.
• List of User Population patients aged 13–17 years with 1 Meningococcal ever.
• List of User Population patients aged 13–17 years without 1 Meningococcal ever.
• List of User Population patients aged 13–17 years with 2 or 3 doses of HPV ever.
• List of User Population patients aged 13–17 years without 2 or 3 doses of HPV ever. If a patient did not have all doses, the IZ will not be listed.

2.4 Behavioral Health Group

2.4.1 Screening, Brief Intervention, and Referral to Treatment (SBIRT)

2.4.1.1 Owner and Contact
JB Kinlacheeny, MPH, IHS Division of Behavioral Health (DBH)

2.4.1.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.4.1.3 Denominators
1. GPRA Developmental: User Population patients age 9 through 75 years who screened positive for risky or harmful alcohol use during the Report Period.

2.4.1.4 Numerators
1. GPRA Developmental: Patients provided a Brief Negotiated Interview (BNI) or Brief Intervention (BI) at an Ambulatory or Telemedicine visit within seven days of screen.
   A. Patients who received a BNI/BI on same day as screen.
   B. Patients who received a BNI/BI one to three days after screen.
   C. Patients who received a BNI/BI four to seven days after screen.
   D. Patients who were referred treatment within seven days of screen.
2.4.1.5 Definitions

Ambulatory Care
- Service Category A (Ambulatory)

Telemedicine Visit
- Service Category M (Telemedicine)

Screening for Risky or Harmful Alcohol Use
Any of the following:
- Exam code 35
- Any Alcohol Health Factor (i.e., CAGE) [F018-F022]
- POV ICD-9: V79.1 Screening for Alcoholism [BGP SCREEN FOR ALCOHOLISM DX]
- CPT G0396, G0397, G0442, G0443, G2011, G2196, G2197, H0049, H0050, 99408, 99409, 3016F [BGP ALCOHOL SCREENING CPTS]
- Measurement in PCC of AUDT, AUDC, CRFT

Positive Screen for Risky or Harmful Alcohol Use
CRS will look for the most recent positive screen during the Report Period, if any. A positive screen is defined as any of the following for the screening performed:
- Exam code 35 Alcohol Screening result of Positive
- Health factor of CAGE result of 1/4, 2/4, 3/4, or 4/4 [F019-F022]
- Any of the following:
  - AUDT result greater than or equal to (≥) 8
  - AUDC result greater than or equal to (≥) 4 (men)
  - AUDC result greater than or equal to (≥) 3 (women)
  - CRFT result greater than or equal to (≥) 2 and CRFT result less than or equal to (≤) 6

BNI/BI
Any of the following documented at the Ambulatory Care visit or within seven days of the Ambulatory Care visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:
- CPT G0396, G0397, G2011, G2200, H0050, 99408, 99409, 96150 through 96155 [BGP BNI CPTS]
- Patient education code containing AOD-BNI, G0396, G0397, G2011, G2200, H0050, 99408, 99409, 96150 through 96155, or SNOMED code 408947007
Referral to Treatment

- Patient education code AOD-TX

2.4.1.6 GPRA 2022 Target

During GPRA Year 2022, achieve the target rate of 13.5% for the proportion of patients ages 9 through 75 years who screened positive for risky or harmful alcohol use and who received a Brief Negotiated Interview (BNI) or Brief Intervention (BI) within seven days of screen.

2.4.1.7 Patient Lists

- List of UP patients ages 9–75 years who were screened for risky or harmful alcohol use.
- List of UP patients ages 9–75 years who were not screened for risky or harmful alcohol use.
- List of UP patients ages 9–75 who screened positive for risky or harmful alcohol use.
- List of UP patients ages 9–75 who received a BNI/BI within seven days of screen.
- List of UP patients ages 9–75 who did not receive a BNI/BI within seven days of screen.
- List of UP patients ages 9–75 who screened positive for risky or harmful alcohol use and who were referred treatment within seven days of screen.
- List of UP patients ages 9–75 who screened positive for risky or harmful alcohol use and who were not referred treatment within seven days of screen.
- List of UP patients ages 9–75 who screened positive for risky or harmful alcohol use and who received a BNI/BI within seven days of screen.
- List of UP patients ages 9–75 who screened positive for risky or harmful alcohol use and who did not receive a BNI/BI within seven days of screen.

2.4.2 Substance Use Disorder (SUD) in Women of Childbearing Age

2.4.2.1 Owner and Contact

JB Kinlacheeny, MPH, IHS Division of Behavioral Health (DBH); CDR Angela Fallon, IHS Office of Clinical and Preventive Services (OCPS)
2.4.2.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.4.2.3 Denominators

1. Female Active Clinical patients ages 14–46.
2. Female User Population patients ages 14–46 years who screened positive for substance abuse.

2.4.2.4 Numerators

1. Patients screened for Substance Use Disorder (SUD).
2. Patients screened for pregnancy intention assessment.
3. Patients screened for both Substance Use Disorder (SUD) and pregnancy intention assessment.
4. Patients screened positive for pregnancy intention.
5. Patients provided a Brief Negotiated Interview (BNI) or Brief Intervention (BI) in Ambulatory Care within seven days of positive screen (with Denominators 2 and 3).
   A. Patients who received a BNI/BI on same day as positive screen.
   B. Patients who received a BNI/BI one to three days after positive screen.
   C. Patients who received a BNI/BI four to seven days after positive screen.
   D. Patients who were referred treatment within seven days of positive screen.
6. Patients with a diagnosis of substance use disorder.

2.4.2.5 Definitions

Pregnancy Definition

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period.
• At least one visit during the Report Period, where the primary provider is not a Community Health Representative (CHR) (Provider code 53) with any of the following:
  – Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
  – CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
  – Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.
• **Miscarriage definition:**
  - POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: 003.9 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

• **Abortion definition:**
  - POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEUDRES]

### Substance Use Disorder Diagnosis

Any of the following at any time prior to the end of the Report Period:

- Diagnosis (POV or Problem List entry where the status is not Deleted) ICD-9: 292.0, 304.0*, 304.7*, 305.5*; ICD-10: F11.*, F12*, F13*, F14*, F15*, F16*, F18*, F19* [BGP SUBSTANCE USE DISORDER DXS]

### Substance Use Disorder Screen

CRS will search for screenings in the following order: 1) screen with a positive result followed by a BNI closest to the date of the screen; 2) screen with a positive result with no BNI; 3) screen with a negative result. Substance use disorder screen defined as any of the following:

- Health Factor 4PS [F145-149] or NIDA Quick Screen [F150-F154]
- Measurement in PCC of DAST-10

### Positive Result for Substance Use Disorder

Any of the following for the screening performed:

- Health factor of 4PS with result other than Screening Negative [F145-148]
- Health factor of NIDA Quick Screen other than Scrn Neg [F151-F154]
- DAST-10 result of greater than (> ) 12

### Pregnancy Intention Assessment

- Health Factor for category Reproductive Plan [C020]

### Positive Result for Pregnancy Intention Assessment

- Health factor Trying to Conceive [F128]
BNI/BI
Any of the following documented at the Ambulatory Care visit or within seven days of the Ambulatory Care visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:

- CPT G0396, G0397, G2011, G2200, H0050, 99408, 99409, 96150 through 96155 [BGP BNI CPTS]
- Patient education code containing AOD-BNI, G0396, G0397, G2011, G2200, H0050, 99408, 99409, 96150 through 96155, or SNOMED code 408947007

Referral to Treatment
- Patient education code AOD-TX

2.4.2.6 Patient Lists

- List of female User Pop patients 14–46 with SUD screening.
- List of female User Pop patients 14–46 without SUD screening.
- List of female User Pop patients 14–46 with pregnancy intention assessment.
- List of female User Pop patients 14–46 without pregnancy intention assessment.
- List of female User Pop patients 14–46 with SUD screening and pregnancy intention assessment.
- List of female User Pop patients 14–46 without SUD screening and pregnancy intention assessment.
- List of female User Pop patients 14–46 with positive SUD screen with pregnancy intention assessment.
- List of female User Pop patients 14–46 with positive SUD screen without pregnancy intention assessment.
- List of female User Pop patients 14–46 with positive SUD screen with BNI/BI within seven days of screen.
- List of female User Pop patients 14–46 with positive SUD screen without BNI/BI within seven days of screen.
- List of pregnant User Pop patients with positive SUD screen with BNI/BI within seven days of screen.
- List of pregnant User Pop patients with positive SUD screen without BNI/BI within seven days of screen.
2.4.3 Suicide Risk Assessment

2.4.3.1 Owner and Contact
Pamela End of Horn, IHS Division of Behavioral Health (DBH)

2.4.3.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.4.3.3 Denominators
1. User Population patients aged 12 years and older who were seen in the ER for suicidal ideation.

2.4.3.4 Numerators
1. Patients with documented suicide risk assessment.

2.4.3.5 Definitions
ER
Clinic code 30

Suicidal ideation
Any of the following during the Report Period:

- POV ICD-9: 300.9, V62.84; ICD-10: R45.851
- BHS Problem code 39

Numerator
For the patient to be included in the numerator, a suicide risk assessment must be documented for each visit to the ER for suicidal ideation during the report period.

Suicide Risk Assessment
Exam code 43

2.4.3.6 Patient Lists
- List of User Population patients seen in the ER with suicide ideation who have a documented suicide risk assessment.
- List of User Population patients seen in the ER with suicide ideation who do not have a documented suicide risk assessment.
2.5 Cardiovascular Disease Related Group

2.5.1 Weight Assessment and Counseling for Nutrition and Physical Activity

2.5.1.1 Owner and Contact
LCDR Kibbe Brown

2.5.1.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.5.1.3 Denominators
1. Active Clinical patients aged 3–17 with no current diagnosis of pregnancy.
   Broken down by gender and age groups: 3–11 and 12–17.

2.5.1.4 Numerators
1. Patients with comprehensive assessment, defined as having BMI documented, counseling for nutrition, and counseling for physical activity during the Report Period.
2. Patients with BMI documented during the Report Period.
3. Patients with counseling for nutrition during the Report Period.
4. Patients with counseling for physical activity during the Report Period.

2.5.1.5 Definitions
Age
Age is calculated at the end of the Report Period.

Pregnancy Definition
Any of the following:
- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period
- At least one visit during the Report Period, where the primary provider is not a Community Health Representative (CHR) (Provider code 53) with any of the following:
- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
- CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
- Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.
Miscarriage Definition
- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

Abortion Definition
- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

BMI
Any of the following during the Report Period:
- CRS calculates BMI at the time the report is run, using NHANES II. For patients aged 18 years and under, a height and weight must be taken on the same day any time during the Report Period. For ages 19 through 50 years, height and weight must be recorded within last five years, not required to be on the same day. For over 50 years of age, height, and weight within last two years not required to be recorded on same day.
- POV ICD-10: Z68.20-Z68.54 [BGP BMI DXS]

Counseling for Nutrition
- CPT 97802-97804, G0270, G0271, G0447, S9449, S9452, S9470 [BGP CPT NUTRITION COUNSELING]
- POV ICD-10: Z71.3 [BGP DIETARY SURVEILLANCE DXS]
- Patient Education codes ending “-N” or “-MNT” or containing Z71.3, 97802 through 97804, G0270, G0271, G0447, S9449, S9452, S9470, or SNOMED 61310001

Counseling for Physical Activity
- CPT G0447, S9451 [BGP CPT PHYSICAL ACTIVITY]
- POV ICD-10: Z71.82 [BGP EXERCISE COUNSELING DXS]
- Patient education codes ending “-EX” (Exercise) or containing Z71.82, G0447, or S9451
2.5.1.6 Patient Lists

- List of Active Clinical patients 3–17 years old with comprehensive assessment.
- List of Active Clinical patients 3–17 years old without comprehensive assessment.

2.5.2 Physical Activity Assessment

2.5.2.1 Owner and Contact

Patient Education Program: Chris Lamer, PharmD
Nutrition Program: Alberta Becenti

2.5.2.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.5.2.3 Denominators

1. User Population patients aged 5 years and older.

2.5.2.4 Numerators

1. Patients assessed for physical activity during the Report Period (with Denominators 1 and 3).
   A. Patients from Numerator 1 who have received exercise education following their physical activity assessment (with Denominators 2 and 4).
   B. Patients from Numerator 1 who have set at least one exercise goal following their physical activity assessment (with Denominators 2 and 4).

2.5.2.5 Definitions

Physical Activity Assessment
Any health factor for category Activity Level [C011] documented during the Report Period.

Exercise Education
- POV ICD-10: Z71.82 [BGP EXERCISE COUNSELING DXS]
• Patient education codes ending “-EX” (Exercise) or containing Z71.82, or SNOMED 304507003

**Exercise Goal**
• Patient Goal with Goal Type of “Physical Activity” and Goal Status of “Goal Set.”

**2.5.2.6 Patient Lists**
• List of User Population patients 5 years of age and older who had a physical activity assessment.
• List of User Population patients 5 years of age and older who did not have a physical activity assessment.
• List of User Population patients 5 years of age and older who had a physical activity assessment and received exercise education.
• List of User Population patients 5 years of age and older who had a physical activity assessment and did not receive exercise education.
• List of User Population patients 5 years of age and older who had a physical activity assessment and set at least one exercise goal.
• List of User Population patients 5 years of age and older who had a physical activity assessment and did not set at least one exercise goal.

**2.5.3 Cardiovascular Disease and Blood Pressure Control**

**2.5.3.1 Owner and Contact**
Dr. Dena Wilson; Chris Lamer, PharmD; and Mark Veazie

**2.5.3.2 National Reporting**
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

**2.5.3.3 Denominators**
1. Active Clinical patients aged 18 years and older.
2. Active coronary heart disease (CHD) patients, defined as Active Clinical patients diagnosed with CHD prior to the Report Period, and at least two visits during the Report Period, and either two CHD-related visits ever or CHD entry on the Problem List.
2.5.3.4 Numerators

1. Patients with blood pressure values documented during the Report Period.

2.5.3.5 Definitions

CHD

Problem List entries must have Date of Onset or Date Entered prior to the Report Period:

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 410.0 through 413.*, 414.0 through 414.9, 429.2; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9, Z95.5 [BGP CHD DXS]

- One or more Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Interventions (PCI) procedures, defined as any of the following:
  - CABG Procedure
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - POV ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
      - SNOMED data set PXRM BGP CABG (Problem List only)
    - CPT 33510 through 33514, 33516 through 33521 through 33523, 33530, 33533 through 33536, 33572, 33500, 35600, S2205 through S2209 [BGP CABG CPTS]
  - PCI Procedure
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - POV ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
      - SNOMED data set PXRM BGP PCI (Problem List only)
    - CPT 92920, 92924, 92928, 92933, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
    - Procedure ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06 through 36.07; ICD-10: 02703**, 02704**,
BP Values (All Numerators)

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded:

- Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation)
- Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)

CRS uses a mean of the last three BPs documented during the Report Period. If three BPs are not available, CRS uses the mean of the last two BPs, or one BP if there is only one documented. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the Blood Pressure (BP) documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 [BGP BP MEASURED CPT, BGP SYSTOLIC BP CPTS, BGP DIASTOLIC BP CPTS] or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS] documented during the Report Period.

2.5.3.6 Patient Lists

- List of Active Clinical patients aged 18 years and older who had their blood pressure assessed.
- List of Active Clinical patients aged 18 years and older who have not had their blood pressure assessed.
- List of Active Clinical patients who have CHD who had their blood pressure assessed.
- List of Active Clinical patients who have CHD who have not had their blood pressure assessed.
### 2.5.4 Appropriate Medication Therapy after a Heart Attack

#### 2.5.4.1 Owner and Contact

Dr. Dena Wilson; Chris Lamer, PharmD; and Mark Veazie

#### 2.5.4.2 National Reporting

NATIONAL (included in IHS Performance Report; *not* reported to OMB and Congress)

#### 2.5.4.3 Denominators

1. Active Clinical patients aged 35 years and older discharged for an Acute Myocardial Infarction (AMI) during the first 51 weeks of the Report Period and who were not readmitted for any diagnosis within seven days of discharge.

#### 2.5.4.4 Numerators

**Note:** These numerators do *not* include refusals.

1. Patients with active prescription for or who have a contraindication or previous adverse reaction to beta blockers.
2. Patients with active prescription for or who have a contraindication or previous adverse reaction to Aspirin (acetylsalicylic acid [ASA]) or other anti-platelet agent.
3. Patients with active prescription for or who have a contraindication or previous adverse reaction to ACEIs or ARBs.
4. Patients with active prescription for or who have a contraindication or previous adverse reaction to statins.
5. Patients with active prescriptions for all post-AMI medications (i.e., beta blocker, ASA or anti-platelet, ACEI or ARB, *and* statin) or who have a contraindication or previous adverse reaction.

#### 2.5.4.5 Definitions

**AMI**

POV ICD-9: 410.0*–410.9*, 412, 429.79; ICD-10: I21.*, I22.*, I23.*, I25.2 [BGP AMI DXS PAMT] with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.
Denominator Exclusions
Patients meeting any of the following conditions will be excluded from the denominator:

- Patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death”
- Patients readmitted for any diagnosis within seven days of discharge
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), T (Status Post)
- Patients with a Provider Narrative beginning with “Consider”, “Doubtful”, “Maybe,” “Possible,” “Perhaps,” “Rule Out,” “R/O,” “Probable,” “Resolved,” “Suspect,” “Suspicious,” “Status Post”

To Be Included in the Numerators
A patient must meet one of the two conditions that follow:

- An active prescription (not discontinued as of discharge date plus seven days and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within seven days after discharge. An “Active” prescription is defined as:

\[
\text{Days Prescribed} > (\text{Discharge Date} + 7 \text{ days}) - \text{Order Date}
\]

- Have a contraindication or previous adverse reaction to the indicated medication.

Contraindications or previous ADR or allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication, or ADR, or allergy will be counted toward meeting the numerator.

Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:

- Rx Date: November 15, 2022
- Discontinued Date: November 19, 2022

Recalculated number of Days Prescribed:
November 19, 2022 – November 15, 2022 = 4

Numerator Logic
In the logic that follows, “ever” is defined as anytime through the end of the Report Period.
Beta Blocker Numerator Logic

Beta Blocker Medications and Combinations

Defined with medication taxonomy BGP PQA BETA BLOCKER MEDS:
- acebutolol, atenolol (+/- chorthalidone), betaxolol, bisoprolol (+/- hydrochlorothiazide), carvedilol, labetalol, metoprolol (+/- hydrochlorothiazide), metoprolol tartrate, nadolol (+/- bendroflumethiazide), nebivolol (+/- valsartan), penbutolol sulfate, pindolol, propranolol (+/-hydrochlorothiazide), timolol maleate

Contraindications to Beta Blockers

Defined as any of the following occurring ever unless otherwise noted:

- **Asthma.** Two diagnoses (POV) of ICD-9: 493*; ICD-10: J45.* [BGP ASTHMA DXS] on different visit dates

- **Hypotension.** One diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 458*; ICD-10: I95.* [BGP HYPOTENSION DXS]
  - SNOMED data set PXRM BGP HYPOTENSION (Problem List only)

- **Heart block greater than 1 degree.** One diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6 [BGP CMS 2/3 HEART BLOCK DXS]
  - SNOMED data set PXRM BGP OVER 1 DEG HEART BLK (Problem List only)

- **Sinus bradycardia.** One diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 427.81; ICD-10: I49.5, R00.1 [BGP SINUS BRADYCARDIA DXS]
  - SNOMED data set PXRM BGP SINUS BRADYCARDIA (Problem List only)

- **COPD.** Two diagnoses on different visit dates of ICD-9: 491.0, 491.1, 491.2*, 491.8, 491.9, 493.2*, 496, 506.4; ICD-10: J41.*, J42, J44.*, J68.4, J68.8 [BGP COPD DXS], or a combination of any of these codes, such as one visit with 491.20 and one with 496

- NMI refusal for any beta blocker at least once during hospital stay through seven days after discharge date
• CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) (old code), G9190 (Documentation of medical reason[s] for not prescribing beta-blocker therapy [e.g., allergy, intolerance, other medical reasons]) at least once during hospital stay through seven days after discharge date

**Adverse Drug Reaction or Documented Beta-Blocker Allergy**

Defined as any of the following occurring ever:

- POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.0 [BGP ADV EFF CARD RHYTH]
- Beta block* entry in ART
- Beta block*, bblock* or b block* contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR BETA BLOCKER

**ASA or Other Anti-Platelet Numerator Logic**

**ASA Medication Codes**

- Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

**Other Anti-Platelet Medication Codes**

- Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

**Contraindications to ASA or Other Anti-Platelets**

Defined as any of the following occurring ever unless otherwise noted:

- Patients with active prescription for Warfarin (Coumadin) at time of arrival or prescribed at discharge, using site-populated BGP CMS WARFARIN MEDS taxonomy
- Hemorrhage diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 459.0; ICD-10: R58 [BGP HEMORRHAGE DXS]
  - SNOMED data set PXRM BGP HEMORRHAGE (Problem List only)
- NMI refusal for any aspirin at least once during hospital stay through seven days after discharge date
- CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) (old code) at least once during hospital stay through seven days after discharge date

**Adverse Drug Reaction, Documented ASA, or Other Anti-Platelet Allergy**

Defined as any of the following occurring ever:

- POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E935.3 [BGP ADV EFF SALICYLATES]; ICD-10: T39.015* or T39.095* [BGP ADV EFF SALICYLATES 10]
- Aspirin entry in ART
- ASA or aspirin contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ASA

**ACEI/ARB Numerator Logic**

**Ace Inhibitor (ACEI) Medication Codes**

Defined with medication taxonomy BGP HEDIS ACEI MEDS:

- **ACEI medications**: (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolopril).
- **Antihypertensive Combinations**: (amlodipine-benazepril, amlodipine-perindopril, benazepril-hydrochlorothiazide, captopril-hydrochlorothiazide, enalapril-hydrochlorothiazide, fosinopril-hydrochlorothiazide, hydrochlorothiazide-lisinopril, hydrochlorothiazide-moexipril, hydrochlorothiazide-quinapril, trandolapril-verapamil).

**Contraindications to ACEI Defined as any of the Following**

- **Pregnancy**: See the definition that follows
- **Breastfeeding**: See the definition that follows
- **Diagnosis Ever for Moderate or Severe Aortic Stenosis**
  - POV or Problem List entry where the status is not Deleted:
    - ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22 [BGP CMS AORTIC STENOSIS DXS]
    - SNOMED data set PXRM BGP MOD SEV AORTIC STEN (Problem List only)
• **NMI refusal** for any ACEI at least once during hospital stay through seven days after discharge date.

**Adverse Drug Reaction or Documented ACEI Allergy**

Defined as any of the following occurring ever:

- POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.6 [BGP ADV EFF ANTIHYPERTEN AGT]; ICD-10: T46.4X5* [BGP ADV EFF ANTIHYPER 10]
- Ace inhibitor or ACEI entry in ART
- Ace i* or ACEI contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ACEI

**ARB Medication Codes**

Defined with medication taxonomy BGP HEDIS ARB MEDS:

- **ARB medications**: Angiotensin II Inhibitors (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)
- **Antihypertensive Combinations**: aliskiren-valsartan, amlodipine-hydrochlorothiazide-olmesartan, amlodipine-hydrochlorothiazide-valsartan, amlodipine-olmesartan, amlodipine-telmisartan, amlodipine-valsartan, azilsartan-chlorthalidone, candesartan-hydrochlorothiazide, eprosartan-hydrochlorothiazide, hydrochlorothiazide-irbesartan, hydrochlorothiazide-losartan, hydrochlorothiazide-olmesartan, hydrochlorothiazide-telmisartan, hydrochlorothiazide-valsartan, sacubitril-valsartan

**Contraindications to ARB**

Defined as any of the following:

- **Pregnancy**: See the definition that follows
- **Breastfeeding**: See the definition that follows
- **Diagnosis ever for moderate or severe aortic stenosis**
  - POV or Problem List entry where the status is not Deleted:
    - ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22 [BGP CMS AORTIC STENOSIS DXS]
    - SNOMED data set PXRM BGP MOD SEV AORTIC STEN (Problem List only)
• **NMI refusal** for any ARB at least once during hospital stay through seven days after discharge date.

**Adverse Drug Reaction or Documented ARB Allergy**
Defined as any of the following occurring ever:

- POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] *and* E942.6 [BGP ADV EFF ANTIHYPERTEN AGT]
- Angiotensin Receptor Blocker or ARB entry in ART
- Angiotensin Receptor Blocker or ARB contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ARB

**Statins Numerator Logic**

**Statin Medications and Combination Products**
Defined with medication taxonomy BGP PQA STATIN MEDS:

- atorvastatin (+/- amlodipine, ezetimibe), fluvastatin, lovastatin (+/- niacin), pitavastatin, pravastatin, rosuvastatin, simvastatin (+/- ezetimibe, niacin, sitagliptin)

**Contraindications to Statins**
Defined as any of the following:

- **Pregnancy**: See the definition that follows
- **Breastfeeding**: See the definition that follows
- **Acute Alcoholic Hepatitis**: Defined as POV or Problem List entry where the status is not Deleted during the Report Period:
  - ICD-9: 571.1; ICD-10: K70.10, K70.11 [BGP ALCOHOL HEPATITIS DXS]
  - SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
- **NMI refusal** for any statin at least once during hospital stay through seven days after discharge date.
Adverse Drug Reaction or Documented Statin Allergy

Defined as any of the following:

- ALT or AST greater than three times the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period
- Creatine Kinase (CK) levels greater than 10 times ULN or CK greater than 10,000 IU/L during the Report Period
- Myopathy or Myalgia, defined as any of the following during the Report Period:
  - POV or Problem List entry where the status is not Deleted:
    - ICD-9: 359.0 through 359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G71.20, G71.220, G71.228, G71.29, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80 through M60.9, M79.1* [BGP MYOPATHY/ MYALGIA]
    - SNOMED 723439002 (Native American myopathy (disorder)) (Problem List only)
  - Any of the following occurring ever:
    - POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.9 [BGP ADV EFF CARDIOVASC NEC]
    - “Statin” or “Statins” (except “Nystatin”) entry in ART
  - “Statin” or “Statins” (except “Nystatin”) contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
  - Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR STATIN

Pregnancy Definition

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period.
- At least one visit during the Report Period where the primary provider is not a CHR (Provider code 53) with any of the following:

– Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

– CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

– Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

**Miscarriage Definition**

- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]

- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion Definition**

- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
• CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]

• Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Breastfeeding Definition**

Any of the following documented during the Report Period:

• The Lactation Status field in Reproductive Factors file set to “Lactating”

• Diagnosis:
  – POV ICD-9: V24.1; ICD-10: O91.03, O91.13, O91.23, O92.03, O92.13, O92.5, O92.70, O92.79, Z39.1 [BGP ECQM BREASTFEED DXS]
  – SNOMED data set PXRM BGP ECQM BREASTFEED

• Breastfeeding Patient Education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N or containing SNOMED data sets PXRM BGP PT ED BREASTFEED or PXRM BGP ECQM BREASTFEED

**All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta blocker, ASA or other anti-platelet, ACEI or ARB, and statin).

**Test Definitions**

**ALT**

• Site-populated taxonomy DM AUDIT ALT TAX

• LOINC taxonomy: 1742-6, 1743-4, 1744-2, 76625-3, 77144-4, 96586-3 [BGP ALT LOINC]

**AST**

• Site-populated taxonomy DM AUDIT AST TAX

• LOINC taxonomy: 1920-8, 30239-8, 88112-8, 96587-1 [BGP AST LOINC]

**Creatine Kinase**

• Site-populated taxonomy BGP CREATINE KINASE TAX

• LOINC taxonomy: 2157-6 [BGP CREATINE KINASE LOINC]
2.5.4.6 Patient Lists

- List of Active Clinical patients aged 35 years and older discharged for AMI with beta-blocker therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI without beta-blocker therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI with ASA therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI without ASA therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI with ACEI or ARB therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI without ACEI or ARB therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI with statin therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI without statin therapy.
- List of Active Clinical patients aged 35 years and older discharged for AMI with all appropriate medications.
- List of Active Clinical patients aged 35 years and older discharged for AMI without all appropriate medications.

2.6 STD-Related Group

2.6.1 HIV Screening

2.6.1.1 Owner and Contact
Richard Haverkate, MPH

2.6.1.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)
2.6.1.3 **Denominators**

1. GPRA Developmental: User Population patients aged 13 through 64 years with no recorded HIV diagnosis prior to the Report Period. Broken down by gender.


3. User Population patients aged 13 through 64 years with first recorded HIV diagnosis during the Report Period.

2.6.1.4 **Numerator**s

1. GPRA Developmental: Patients who were screened for HIV during the Report Period (with Denominators 1 and 2).

   **Note:** This numerator does *not* include refusals.

   A. Patients with a positive result.
   B. Patients with a negative result.
   C. Patients with no result.

2. Patients who were screened for HIV in the past five years (with Denominator 1).

   **Note:** This numerator does *not* include refusals.

3. Patients who were screened for HIV at any time before the end of the Report Period (with Denominator 2).

   **Note:** This numerator does *not* include refusals.

4. GPRA Developmental: Number of HIV screens provided to User Population patients during the Report Period, where the patient was not diagnosed with HIV any time prior to the screen.

   **Note:** This numerator does *not* have a denominator. This measure is a total count only, not a percentage.

5. Patients with CD4 count within 90 days of initial HIV diagnosis (with Denominator 3).

   A. Patients with CD4 less than (<) 200.
   B. Patients with CD4 greater than or equal to (≥) 200 and less than or equal to (≤) 350.
C. Patients with CD4 greater than (> 350) and less than or equal to (≤ 500).
D. Patients with CD4 greater than (< 500).
E. Patients with no CD4 result.

2.6.1.5 Definitions

HIV
Any of the following documented any time prior to the beginning of the Report Period:
- POV or Problem List entry where the status is not Deleted:
  - ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
  - SNOMED data set PXRM HIV (Problem List only)

HIV Screening
- CPT 80081, 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806, 87901, 87906 [BGP CPT HIV TESTS]
- LOINC taxonomy: 10901-7, 10902-5, 11078-3, 11079-1, 11080-9, 11081-7, 11082-5, 12855-3, 12856-1, 12857-9, 12858-7, 12859-5, 12870-2, 12871-0, 12872-8, 12875-1, 12876-9, 12893-4, 12894-2, 12895-9, 13499-9, 13920-4, 14092-1, 14126-7, 16132-3, 16974-8, 16975-5, 16978-9, 18396-2, 19110-6, 21007-0, 21009-6, 21331-4, 21332-2, 21334-8, 21335-5, 21336-3, 21337-1, 21338-9, 21339-7, 21340-5, 22356-0, 22357-8, 22358-6, 23876-6, 24012-7, 28004-0, 28052-9, 29327-4, 29893-5, 30245-5, 30361-0, 31072-2, 31077-0, 31201-7, 31430-2, 32571-2, 32602-5, 32827-8, 32842-7, 33508-3, 33660-2, 33806-1, 33807-9, 33866-5, 34591-8, 34592-6, 34699-9, 35437-3, 35438-1, 35439-9, 35440-7, 35441-5, 35442-3, 35443-1, 35444-9, 35445-6, 35446-4, 35447-2, 35448-0, 35449-8, 35450-6, 35452-2, 35564-4, 35565-1, 38998-1, 40437-6, 40438-4, 40439-2, 40732-0, 40733-8, 41143-9, 41144-7, 41145-4, 41290-8, 42339-2, 42600-7, 42627-0, 42768-2, 43008-2, 43009-0, 43010-8, 43011-6, 43012-4, 43013-2, 43185-8, 43599-0, 44531-2, 44532-0, 44533-8, 44607-0, 44871-2, 44872-0, 44873-8, 45212-8, 47029-4, 48023-6, 48345-3, 48346-1, 49483-1, 49580-4, 49718-0, 49905-3, 49965-7, 51786-2, 51866-2, 5220-9, 5221-7, 5222-5, 5223-3, 5224-1, 5225-8, 53379-4, 53601-1, 53825-6, 54086-4, 56888-1, 57974-8, 57975-5, 57976-3, 57977-1, 57978-9, 58900-2, 59052-1, 59419-2, 62456-9, 6429-5, 6430-3, 6431-1, 68961-2, 69668-2, 73905-2, 73906-0, 74856-6, 75622-1, 75666-8, 77685-6, 7917-8, 7918-6, 7919-4, 80203-3, 80387-4, 81641-3, 83101-6, 85037-0, 85361-4, 85368-9, 85686-4, 86233-4, 88453-6, 89365-1, 89374-3, 95524-5, 95523-7, 96273-8, 96556-6, 96557-4, 9660-2, 9661-0, 9662-8, 9663-6, 9664-4, 9665-1, 9666-9,
9667-7, 9668-5, 9669-3, 97860-1, 97861-9, 9821-0, 9836-8, 9837-6 [BGP HIV TEST LOINC CODES]

- Site-populated taxonomy BGP HIV TEST TAX

For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

Positive HIV Result

- Positive result for HIV Screening test, defined as “Positive,” “P,” “Pos,” “R,” “Reactive,” “Repeatedly Reactive,” “+,” or containing “>”
- HIV diagnosis defined as any of the following documented any time after the HIV screening:
  - POV or Problem List codes ICD-9: 042, 042.0–044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]

If patient has a positive result for either an HIV-1 or HIV-2 test (regardless of any other results), it will be considered a positive result.

Negative HIV Result

Negative result for HIV Screening test, defined as “Negative,” “N,” “Neg,” “NR,” “NonReactive,” “Non-Reactive,” or “-”

No Result

Any screening that does not have a positive or negative result.

CD4 Count

Searches for most recent CD4 test with a result during the Report Period. If none found, CRS searches for the most recent CD4 test without a result.

CD4 Test defined as:

- CPT 86359, 86360, 86361, G9214 [BGP CD4 CPTS]

- Site-populated taxonomy BGP CD4 TAX
2.6.1.6 **Patient Lists**

- List of User Population patients aged 13–64 years with a documented HIV test.
- List of User Population patients aged 13–64 years without a documented HIV test.
- List of User Population patients aged 13–64 years with a documented HIV test and positive result.
- List of User Population patients aged 13–64 years with a documented HIV test and negative result.
- List of User Population patients aged 13–64 years with a documented HIV test and no result.
- List of User Population patients aged 13–64 years with a documented HIV test in the past five years.
- List of User Population patients aged 13–64 years without a documented HIV test in the past five years.
- List of Male User Population patients aged 25–45 years with a positive HIV result.
- List of Male User Population patients aged 25–45 years without a positive HIV result.
- List of Male User Population patients aged 25–45 years with a documented HIV test ever.
- List of Male User Population patients aged 25–45 years without documented an HIV test ever.
- List of User Population patients with documented HIV test.
- List of HIV+ User Population patients aged 13–64 years with CD4 count.
- List of HIV+ User Population patients aged 13–64 years without CD4 count.

2.6.2 **HIV Quality of Care**

2.6.2.1 **Owner and Contact**

Richard Haverkate, MPH

2.6.2.2 **National Reporting**

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)
2.6.2.3 Denominators

1. User Population patients aged 13 years and older with at least two direct care visits, (i.e., not contract or PRC) during the Report Period with Human Immunodeficiency Virus (HIV) diagnosis and one HIV visit in the last six months.

2.6.2.4 Numerators

1. Patients who received CD4 test only (without HIV viral load) during the Report Period.

2. Patients who received HIV viral load only (without CD4), during the Report Period.

3. Patients who received both CD4 and HIV viral load tests during the Report Period.

4. Total Numerators 1, 2, and 3.

5. Patients who received at least one prescription for an Antiretroviral medication.

2.6.2.5 Definitions

HIV

Diagnosis:

- POV ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
- SNOMED data set PXRM HIV (POV only)

Lab Test CD4

- CPT 86359, 86360, 86361, G9214 [BGP CD4 CPTS]
- Site-populated taxonomy BGP CD4 TAX
HIV Viral Load

- CPT 87536, 87539, G9242, G9243 [BGP HIV VIRAL LOAD CPTS]
- LOINC taxonomy: 10351-5, 10682-3, 20447-9, 21008-8, 21333-0, 23876-6, 24013-5, 25835-0, 25836-8, 25841-8, 25842-6, 29539-4, 29541-0, 30245-5, 41513-3, 41514-1, 41515-8, 47359-5, 48510-2, 48511-0, 48551-6, 48552-4, 49890-7, 5017-9, 5018-7, 51780-5, 51786-2, 59419-2, 62469-2, 69354-9, 70241-5, 74854-1, 74855-8, 78007-2, 78008-0, 78009-8, 78010-6, 81652-0, 86548-5 [BGP VIRAL LOAD LOINC CODES]
- Site-populated taxonomy BGP HIV VIRAL TAX

Antiretroviral Medication

- Defined with medication taxonomy BGP PQA ANTIRETROVIRAL MEDS. Medications must not have a comment of RETURNED TO STOCK.

Antiretroviral medications are:

- Single Agents (abacavir, atazanavir, darunavir, delavirdine, didanosine, dolutegravir, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, fosamprenavir, indinavir, lamivudine, maraviroc, nelfinavir, nevirapine, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, tipranavir, zidovudine).

2.6.2.6 Patient Lists

- List of patients aged 13 years and older with an HIV diagnosis during the Report Period who received a CD4 test only.
- List of patients aged 13 years and older with an HIV diagnosis during the Report Period who did not receive a CD4 test only.
- List of patients aged 13 years and older with an HIV diagnosis during the Report Period who received an HIV viral load only.
- List of patients aged 13 years and older with an HIV diagnosis during the Report Period who did not receive an HIV viral load only.
- List of patients aged 13 years and older with an HIV diagnosis during the Report Period who received CD4 and HIV viral load.
• List of patients aged 13 years and older with an HIV diagnosis during the Report Period who did not receive CD4 and HIV viral load.

• List of patients aged 13 years and older with an HIV diagnosis during the Report Period who received CD4 or HIV viral load.

• List of patients aged 13 years and older with HIV diagnosis during the Report Period who did not receive CD4 or HIV viral load.

• List of patients aged 13 years and older with an HIV diagnosis during the Report Period who received a prescription for an antiretroviral medication.

• List of patients aged 13 years and older with HIV diagnosis during the Report Period who did not receive a prescription for an antiretroviral medication.

2.6.3 Hepatitis C Screening

2.6.3.1 Owner and Contact
Brigg Reilley

2.6.3.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.6.3.3 Denominators
1. User Population patients born between 1945 and 1965 with no recorded Hepatitis C diagnosis prior to the Report Period.

2. User Population with documented positive Ab result or Hep C diagnosis ever. Broken down by age group of patients born between 1945 and 1965.

3. User Population patients with positive Ab result or Hep C diagnosis ever and with positive Hepatitis C confirmation result ever. Broken down by age group of patients born between 1945 and 1965.

4. User Population patients ages 18 and older with no recorded Hep C diagnosis prior to the Report Period.

5. User Population patients ages 13 through 64.

### Numerators

1. Patients screened for Hepatitis C ever (Ab test) (with Denominators 1 and 4).
   - A. Patients with a positive result.
   - B. Patients with a negative result.

2. Patients with documented positive Ab result ever (with Denominator 2).

3. Patients with documented Hep C diagnosis ever (with Denominators 2 and 5).

4. Patients who were given a Hepatitis C confirmation test (with Denominator 2).
   - A. Patients with a positive result.
   - B. Patients with a negative result.

5. Patients who ever had a negative confirmation test 12 weeks or greater after a positive confirmation test (cured) (with Denominator 3).

6. Patients who had a negative confirmation test 12 weeks or greater after their most recent positive confirmation test (currently cured) (with Denominator 3).

7. Patients with first Hep C diagnosis during the Report Period (with Denominator 5).

8. Patients screened for Hepatitis C (Ab test) during the past 20 months (with Denominator 6).
   - A. Patients with a positive result.

### Definitions

#### Hepatitis C Diagnosis

Any of the following:
- POV or Problem List entry where the status is not Inactive or Deleted:
  - ICD-9: 070.41, 070.44, 070.51, 070.54, 070.70 through 070.71, V02.62;
  - ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21, Z22.52 [BGP HEPATITIS C DXS]
  - SNOMED data set PXRM HEPATITIS C (Problem List only)

#### Pregnancy

Any of the following:
- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period.
- At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following:
  - Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
  - CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.

The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to “Yes.” The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

- **Miscarriage**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

- **Abortion**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Hepatitis C Screening (Ab Test)**

- CPT 86803

- LOINC taxonomy: 11077-5, 11259-9, 13125-0, 13955-0, 16128-1, 16129-9, 16936-7, 22324-8, 22325-5, 22326-3, 22327-1, 22328-9, 22329-7, 23870-9, 23871-7, 24363-4, 33462-3, 34162-8, 40726-2, 44813-4, 44831-6, 47365-2, 47441-1, 48159-8, 49846-9, 51824-1, 5198-7, 5199-5, 53376-0, 54914-7, 57006-9, 72376-7, 75886-2, 75887-0, 75888-8, 79189-7, 81116-6, 89359-4, 92889-5, 92890-3, 95237-4, 95206-9, 9608-1, 9609-9, 9610-7 [BGP HEP C TEST LOINC CODES]

- Site-populated taxonomy BGP HEP C TEST TAX
**Hepatitis C Confirmation Test**

Any of the following documented any time prior to the end of the Report Period:

- CPT 86804, 87520, 87521, 87522, G9203, G9207, G9209 [BGP HEP C CONF CPTS]

- LOINC taxonomy: 10676-5, 11011-4, 11259-9, 20416-4, 20571-6, 29609-5, 32286-7, 34703-9, 34704-7, 38180-6, 38998-1, 41996-0, 42003-4, 42617-1, 47252-2, 48574-8, 48575-5, 48576-3, 48796-7, 49372-6, 49376-7, 49380-9, 49605-9, 49758-6, 50023-1, 5010-4, 5012-0, 53825-6, 59052-1, 6422-0, 74856-6, 75886-2, 75887-0, 75888-8, 82512-5, 82513-3, 88453-6, 92731-9, 96273-8 [BGP HEP C CONF TEST LOINC CODES]

- Site-populated taxonomy BGP HEP C CONF TEST TAX

If patient has more than one confirmatory test, CRS will first look for a test with a positive result, and if none is found, then will look for a test with a negative result. If there is no test with a result, CRS will use the first test documented.

For patients ever cured numerator, there must be 12 or more weeks between a positive and negative confirmation test result.

**Positive Ab Test Result**

Defined as a result starting with “>” or containing “Pos,” “React,” or “Detec.”

**Negative Ab Test Result**

Defined as result starting with “<,” or containing “Neg,” “Non,” “Not,” or “None.”

**Positive Confirmation Test Result**

Defined as any number greater than zero, a result starting with “>” or “<,” or containing “Pos,” “React,” or “Detec.”

**Negative Confirmation Test Result**

Defined as a result containing “Neg,” “Non,” “Not,” or “None.”

### 2.6.3.6 Patient Lists

- List of patients born between 1945 and 1965 with no prior Hepatitis C diagnosis who were ever screened for Hepatitis C.
- List of patients born between 1945 and 1965 with no prior Hepatitis C diagnosis or screening who were ever screened for Hepatitis C.
- List of patients with Hep C screening and positive result.
- List of patients with Hep C screening and negative result.
- List of patients with positive Ab result.
- List of patients with Hep C diagnosis.
- List of patients with Hep C Dx/positive Ab result who were given Hep C confirmatory test.
- List of patients with Hep C Dx/positive Ab result who were not given Hep C confirmatory test.
- List of patients with Hep C confirmatory test and positive result.
- List of patients with Hep C confirmatory test and negative result.
- List of patients with positive confirmatory test who were ever cured.
- List of patients with positive confirmatory test who were never cured.
- List of patients with positive confirmatory test who are currently cured.
- List of patients with positive confirmatory test who are not currently cured.
- List of User Population patients 18+ with no prior Hep C diagnosis who were ever screened for Hep C.
- List of User Population patients 18+ with no prior Hep C diagnosis who were never screened for Hep C.
- List of User Population patients 18+ with Hep C screening and positive result.
- List of User Population patients 18+ with Hep C screening and negative result.
- List of pregnant patients with no prior Hep C diagnosis who were screened for Hep C in the past 20 months.
- List of pregnant patients with no prior Hep C diagnosis who were not screened for Hep C in the past 20 months.
- List of pregnant patients with Hep C screening and positive result.

2.6.4 Chlamydia Testing

2.6.4.1 Owner and Contact
Epidemiology Program: Andria Apostolou, PhD, MPH

2.6.4.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)
2.6.4.3 Denominators


3. Female Active Clinical patients aged 16–29 who are identified as sexually active with no hospice indicator during the Report Period. Broken down by age groups: 16–20, 21–24, and 25–29.


2.6.4.4 Numerators

1. Patients tested for Chlamydia trachomatis during the Report Period.

   Note: This numerator does not include refusals.

2. Patients with documented refusal during the Report Period.

2.6.4.5 Definitions

Hospice

- CPT 99377, 99378, G9473 through G9479, G9687, M1022, M1025, M1026, M1059, M1067 [BGP CPT HOSPICE]

- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

Sexually Active
Any of the following during the Report Period:

- POV ICD-9: 042, 054.10 through 054.12, 054.19, 078.11, 078.88, 079.4, 079.51 through 079.53, 079.88, 079.98, 091.* through 097.*, 098.0 through 098.11, 098.15 through 098.31, 098.35 through 098.89, 099.*, 131.*, 302.76, 339.82, 614.*, 615.*, 622.3, 623.4, 625.0, 626.7, 628.*, 795.*, 796.7*, 996.32, V01.6, V02.7, V02.8, V08, V15.7, V24.*, V25.*, V26.0 through V26.51, V26.81 through V26.9, V27.*, V45.5*, V61.5 through V61.7, V69.2, V72.31 through V72.42, V73.8*, V74.5, V76.2; ICD-10: A34, A51.* through A53.*, A54.00 through A54.1, A54.21, A54.24 through A54.9, A55 through A58, A59.00 through A59.01, A59.03 through A59.9, A60.00, A60.03 through A60.9, A63.*, A64, B20, B97.33 through B97.35, B97.7, F52.6, F53*, G44.82, N70.*, N71.*, N93.0, N94.1, N96, N97.*, O*, T38.4*, T83.3*, Z20.2, Z21, Z22.4, Z30.* through Z34.*, Z36*, Z37.*, Z39.*, Z3A.*, Z64.0 through Z64.1, Z72.51 through Z72.53, Z79.3, Z92.0, Z97.5, Z98.51 [BGP SEXUAL ACTIVITY DXS]

- Procedure codes ICD-9: 69.01, 69.02, 69.51, 69.52, 69.7, 72.*, 73.*, 74.*, 75.*, 88.78, 97.24, 97.71, 97.73 [BGP SEXUAL ACTIVITY PROCEDURES]

- CPT 11975 through 11977, 57022, 57170, 58300, 58301, 58600, 58605, 58611, 58615, 58970 through 58976, 59000 through 59899, 76801, 76805, 76811, 76813, 76815 through 76828, 76941, 76945, 76946, 80055, 80081, 82105, 82106, 82143, 82731, 83632, 83661 through 83664, 84163, 84704, 86592, 86593, 86631, 86632, 87110, 87164, 87166, 87270, 87320, 87490 through 87492, 87590 through 87592, 87620 through 87622, 87624, 87625, 87660, 87661, 87800, 87801, 87808, 87810, 87850, 88141 through 88155, 88164 through 88175, 88235, 88267, 88269, G0101, G0123, G0124, G0141 through G0148, G0475, G0476, H1000, H1001, H1003 through H1005, P3000, P3001, Q0091, S0199, S4981, S8055

- Dispensed prescription contraceptives
- Pregnancy, miscarriage, or abortion
- Pregnancy test with no prescription for isotretinoin or x-ray on the date of the pregnancy test or the six days after the pregnancy test.

Pregnancy Definition

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to “Yes” during the Report Period
- At least one visit during the Report Period, where the primary provider is not a Community Health Representative (CHR) (Provider code 53) with any of the following:
- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
- CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Pharmacy-only visits (clinic code 39) will not count toward the visit.

Miscarriage Definition
- Any of the following: POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]
**Abortion Definition**
Any of the following:
- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Pregnancy Test**
- CPT 81025, 84702, 84703

**Prescription Contraceptives**
Medication taxonomy BGP HEDIS CONTRACEPTION MEDS.

**Isotretinoin Medications**
Medication taxonomy BGP HEDIS ISOTRETINOIN MEDS.
- Medication is: isotretinoin

**X-Ray**
- Radiology or CPT 70010 through 76499

**Chlamydia Test**
- POV ICD-9: V73.88, V73.98 [BGP CHLAMYDIA SCREEN DXS]
- CPT 86631, 86632, 87110, 87270, 87320, 87490 through 87492, 87810, 3511F, G9228 [BGP CHLAMYDIA CPTS]
- Site-populated taxonomy BGP GPRA CHLAMYDIA TESTS
LOINC taxonomy: 14463-4, 14464-2, 14465-9, 14467-5, 14468-3, 14470-9, 14471-7, 14472-5, 14474-1, 14509-4, 14510-2, 14511-0, 14513-6, 16600-9, 16601-7, 16602-5, 21189-6, 21190-4, 21191-2, 21192-0, 21613-5, 23838-6, 31771-9, 31772-7, 31774-3, 31775-0, 31776-8, 31777-6, 34710-4, 36902-5, 36903-3, 42931-6, 43304-5, 43404-3, 43405-0, 43406-8, 44806-8, 44807-6, 45067-6, 45068-4, 45069-2, 45070-0, 45072-6, 45073-4, 45074-2, 45075-9, 45076-7, 45077-5, 45078-3, 45079-1, 45080-9, 45081-7, 45082-5, 45083-3, 45084-1, 45085-8, 45086-6, 45089-0, 45090-8, 45091-6, 45092-4, 45093-2, 45094-0, 45095-7, 45096-5, 45097-3, 45098-1, 45099-9, 45100-5, 45101-3, 45102-1, 45103-9, 47211-8, 47212-6, 49096-1, 4993-2, 50387-0, 53925-4, 53926-2, 557-9, 57287-5, 57288-3, 6349-5, 6354-5, 6355-2, 6356-0, 6357-8, 64017-7, 70161-5, 70162-3, 70163-1, 70164-9, 72828-7, 77577-5, 80363-5, 80364-3, 80365-0, 80367-6, 82306-2, 88221-7, 89648-0, 90357-5, 90358-3, 91860-7, 91861-5, 91873-0, 92683-2, 92684-0, 96612-7, 99105-9, 99778-3, 100120-5, 100121-3 [BGP CHLAMYDIA LOINC CODES]

**Refusal**

Refusal of lab or CPT code 86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228 [BGP CHLAMYDIA CPTS] during the Report Period.

### 2.6.4.6 Patient Lists

- List of Active Clinical patients with documented Chlamydia screening.
- List of Active Clinical patients without documented Chlamydia screening.
- List of Active Clinical patients with documented Chlamydia screening refusal.
- List of Active Clinical patients who are sexually active with documented Chlamydia screening.
- List of Active Clinical patients who are sexually active without documented Chlamydia screening.

### 2.6.5 STI Screening

#### 2.6.5.1 Owner and Contact

Andria Apostolou, PhD, MPH

#### 2.6.5.2 Denominators

1. GPRA Developmental: HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.
2. HIV/AIDS screenings needed for key STI incidents for User Population patients that occurred during the defined period.

2.6.5.3 Numerators

1. GPRA Developmental: Number of needed HIV/AIDS screenings performed from one month prior to the date of first STI diagnosis of each incident through two months after.

   **Note:** This numerator does not include refusals.

2. Patients with documented HIV screening refusal during the Report Period.

2.6.5.4 Definitions

**Key STIs**

Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Key STIs defined with the following POVs:

- **Chlamydia:** ICD-9: 079.88, 079.98, 099.41, 099.50 through 099.59; ICD-10: A56.*, A74.81 through A74.9
- **Gonorrhea:** ICD-9: 098.0 through 098.89; ICD-10: A54.*, O98.2*
- **HIV/AIDS:** ICD-9: 042, 042.0 through 044.9, 079.53, 795.71, V08; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
- **Syphilis:** ICD-9: 090.0 through 093.9, 094.1 through 097.9; ICD-10: A51.* through A53.*

**Logic for Identifying Patients Diagnosed with Key STI (numerator #1)**

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

**Logic for Identifying Separate Incidents of Key STIs (numerator #2)**

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs two months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day period as the first STI counts as a separate incident.
Table 2-1 is an example of a patient with multiple incidents of single STI.

Table 2-1: Example of patient with multiple incidents of single STI

<table>
<thead>
<tr>
<th>Date</th>
<th>Visit</th>
<th>Total Incidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 1, 2021</td>
<td>Patient screened for Chlamydia</td>
<td>0</td>
</tr>
<tr>
<td>August 8, 2021</td>
<td>Patient diagnosed with Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>October 15, 2021</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>October 25, 2021</td>
<td>Follow-up for Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>November 15, 2021</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>March 1, 2022</td>
<td>Patient diagnosed with Chlamydia</td>
<td>3</td>
</tr>
</tbody>
</table>

**Denominator Logic for Needed Screenings**

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed HIV screening tests denominator, the count will be derived from the number of separate non-HIV STI incidents. HIV screening tests are recommended for the following key STIs: Chlamydia, Gonorrhea, Syphilis.

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

- Only one screening for HIV is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening is needed for HIV/AIDS.
- A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

**Numerator Logic**

To be counted in the numerator, each needed screening in the denominator must have a corresponding lab test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through two months after the STI incident.

**HIV/AIDS Screening**

Any of the following during the specified time period:

- CPT 80081, 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806, 87901, 87906 [BGP CPT HIV TESTS]
- Site-populated taxonomy BGP HIV TEST TAX
• LOINC taxonomy: 10901-7, 10902-5, 11078-3, 11079-1, 11080-9, 11081-7, 11082-5, 12855-3, 12856-1, 12857-9, 12858-7, 12859-5, 12870-2, 12871-0, 12872-8, 12875-1, 12876-9, 12878-9, 12893-4, 12894-2, 12895-9, 13499-9, 13920-4, 14092-1, 14126-7, 16132-3, 16974-8, 16975-5, 16976-3, 16977-1, 16978-9, 18396-2, 19110-6, 21007-0, 21009-6, 21331-4, 21332-2, 21334-8, 21335-5, 21336-3, 21337-1, 21338-9, 21339-7, 21340-5, 22356-0, 22357-8, 22358-6, 23876-6, 24012-7, 28004-0, 28052-9, 29327-4, 29893-5, 30245-5, 30361-0, 31072-2, 31073-0, 31201-7, 31430-2, 32571-2, 32602-5, 32827-8, 33508-3, 33660-2, 33806-1, 33807-9, 33866-5, 34591-8, 34592-6, 34699-9, 35437-3, 35438-1, 35439-9, 35440-7, 35441-5, 35442-3, 35443-1, 35444-9, 35445-6, 35446-4, 35447-2, 35448-0, 35449-8, 35450-6, 35452-2, 35564-4, 35565-1, 38998-1, 40437-6, 40438-4, 40439-2, 40732-0, 40733-8, 41143-9, 41144-7, 41145-4, 41290-8, 42339-2, 42600-7, 42627-0, 42768-2, 43008-2, 43009-0, 43010-8, 43011-6, 43012-4, 43013-2, 43185-8, 43599-0, 44531-2, 44532-0, 44533-8, 44607-0, 44871-2, 44872-0, 44873-8, 45212-8, 47029-4, 48023-6, 48345-3, 48346-1, 49483-1, 49580-4, 49718-0, 49905-3, 49965-7, 51786-2, 51866-2, 5220-9, 5221-7, 5222-5, 5223-3, 5224-1, 5225-8, 53379-4, 53601-1, 53825-6, 54086-4, 56888-1, 57974-8, 57975-5, 57976-3, 57977-1, 57978-9, 58900-2, 59052-1, 59419-2, 62456-9, 6429-5, 6430-3, 6431-1, 68961-2, 69668-2, 73905-2, 73906-0, 7917-8, 7918-6, 7919-4, 9660-2, 9661-0, 9662-8, 9663-6, 9664-4, 9665-1, 9666-9, 9667-7, 9668-5, 9669-3, 97860-1, 97861-9, 9821-0, 9836-8, 9837-6 [BGP HIV TEST LOINC CODES]

HIV Screening Refusal
Refusal of Lab or CPT code 80081, 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806, 87901, 87906 [BGP CPT HIV TESTS] during the Report Period.

2.6.5.5 Patient Lists

• List of Active Clinical patients diagnosed with an STI who were screened for HIV.

• List of Active Clinical patients diagnosed with an STI who were not screened for HIV or who had a prior HIV diagnosis.

• List of Active Clinical patients diagnosed with an STI with an HIV-screening refusal.

• List of User Population patients diagnosed with an STI who were screened for HIV.

• List of User Population patients diagnosed with an STI who were not screened for HIV or who had a prior HIV diagnosis.
2.7 Other Clinical Measures Group

2.7.1 Proportion of Days Covered by Medication Therapy

2.7.1.1 Owner and Contact
Chris Lamer, PharmD

2.7.1.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.7.1.3 Denominators
1. User Population patients aged 18 years and older who had two or more prescriptions for beta blockers and no hospice indicator during the Report Period.

2. User Population patients aged 18 years and older who had two or more prescriptions for RAS Antagonists and no documented history of ESRD or one or more prescriptions for ARB/Nephrilysin inhibitor combination medications during the Report Period.

3. User Population patients aged 18 years and older who had two or more prescriptions for calcium channel blockers (CCB) and no hospice indicator during the Report Period.

4. User Population patients aged 18 years and older who had two or more prescriptions for biguanides and no documented history of ESRD and no hospice indicator during the Report Period.

5. User Population patients aged 18 years and older who had two or more prescriptions for sulfonylureas and no documented history of ESRD and no hospice indicator during the Report Period.

6. User Population patients aged 18 years and older who had two or more prescriptions for thiazolidinediones and no documented history of ESRD and no hospice indicator during the Report Period.

7. User Population patients aged 18 years and older who had two or more prescriptions for DiPeptidyl Peptidase (DPP)-IV Inhibitors and no documented history of ESRD and no hospice indicator during the Report Period.
8. User Population patients aged 18 years and older who had two or more prescriptions for Diabetes All Class medications and no documented history of ESRD during the Report Period.

9. User Population patients aged 18 years and older who had two or more prescriptions for statins during the Report Period.

10. User Population patients aged 18 years and older who had two or more prescriptions for non-warfarin oral anticoagulants and no hospice indicator during the Report Period.

11. User Population patients aged 18 years and older who had three or more prescriptions for antiretroviral agents and no hospice indicator during the Report Period.

12. User Population patients with COPD who had two or more prescriptions for long-acting inhaled bronchodilators and no prescriptions for nebulized bronchodilators or hospice indicator during the Report Period.

13. User Population patients aged 18 years and older who had two or more prescriptions for non-infused disease-modifying agents treating multiple sclerosis (MS) totaling a 56-day supply or more and no prescriptions for infused medications treating MS or hospice indicator during the Report Period.

2.7.1.4 Numerators

1. Patients with Proportion of Days Covered (PDC) 80% or more during the Report Period.

2. Patients with a gap in medication therapy 30 days or longer.

3. Patients with PDC 90% or higher during the Report Period (with Denominator 11).

2.7.1.5 Definitions

Denominator Inclusion

Patients must have at least two prescriptions for that particular type of medication (or at least three prescriptions for antiretroviral medication) on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

Note: Outside medications and e-prescribed medications (prescription number begins with “X” or days’ supply is zero) will not be included in these measures.
For the Non-warfarin anticoagulants measures, the two unique dates of service must be at least 180 days apart and the patient must have received greater than a 60-day supply of the medication during the Report Period. Patients who received one or more prescriptions for warfarin, low molecular weight heparin (LMWH), heparin, or an SC Factor Xa inhibitor (defined by medication taxonomy BGP PQA WARFARIN) will be excluded from the denominator.

**Index Prescription Start Date**

The date when the medication was first dispensed within the Report Period. For all measures except Non-warfarin anticoagulants, this date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

**Medications**

Medications are defined with the following taxonomies:

- **BGP PQA BETA BLOCKER MEDS**
  - Beta-blocker Medications and Combinations (acebutolol, atenolol [+- chorthalidone], betaxolol, bisoprolol [+-hydrochlorothiazide], carvedilol, labetalol, metoprolol [+-hydrochlorothiazide], metoprolol tartrate, nadolol [+-bendroflumethiazide], nebivolol [+- valsartan], penbutolol sulfate, pindolol, propranolol [+-hydrochlorothiazide], timolol maleate)

- **BGP PQA RASA MEDS**
  - Angiotensin Converting Enzyme Inhibitor Medications and Combinations (benazepril [+- amldipine, hydrochlorothiazide], captopril [+- hydrochlorothiazide], enalapril [+- hydrochlorothiazide], fosinopril [+- hydrochlorothiazide], lisinopril [+- hydrochlorothiazide], moexipril [+- hydrochlorothiazide], perindopril [+- amldipine], quinapril [+- hydrochlorothiazide], ramipril, trandolopril [+- verapamil]); Angiotensin II Inhibitor Medications and Combinations (azilsartan [+- chlorthalidone], candesartan [+- hydrochlorothiazide], eprosartan [+- hydrochlorothiazide], irbesartan [+- hydrochlorothiazide], losartan [+- hydrochlorothiazide], olmesartan [+- amldipine, hydrochlorothiazide], telmisartan [+- amlodipine, hydrochlorothiazide], valsartan [+- amlodipine, hydrochlorothiazide nebivolol]); Direct Renin Inhibitor Medications and Combinations (aliskiren [+- amlodipine, hydrochlorothiazide])

- **BGP PQA CCB MEDS**
  - Calcium-Channel Blocker Medications and Combinations (amlodipine [+- akiaskiren, atorvastatin, benazepril, hydrochlorothiazide, olmesartan, perindopril, telmisartan, trandolapril, valsartan], diltiaz, felodipine, isradipine, nicardipin, nifedipine [long acting only], nisoldipine, verapamil [+- trandolapril])
• BGP PQA BIGUANIDE MEDS
  - Biguanide Medications and Combinations (metformin +/- alogliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glipizide, glyburide, linagliptin, pioglitazone, repaglinide, rosiglitazone, saxagliptin, sitagliptin))

• BGP PQA SULFONYLUREA MEDS
  - Sulfonylurea Medications and Combinations (chlorpropamide, glimepiride +/- pioglitazone, glipizide +/- metformin, glyburide +/- metformin, tolazamide, tolbutamide)

• BGP PQA THIAZOLIDINEDIONE MEDS
  - Thiazolidinedione Medications and Combinations (pioglitazone +/- alogliptin, glimepiride, metformin), rosiglitazone +/- metformin)

• BGP PQA DPP IV MEDS
  - DPP-IV Inhibitor Medications and Combinations (alogliptin +/- metformin, pioglitazone), linagliptin +/- empagliflozin, metformin, saxagliptin +/- metformin, dapagliflozin, sitagliptin +/- metformin, erugliflozin, sitagliptin))

• BGP PQA DIABETES ALL CLASS
  - Biguanide medications (see list above); Sulfonylurea medications (see list above); Thiazolidinedione medications (see list above); DPP-IV Inhibitor medications (see list above); Incretin Mimetic Agents (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide); Meglitinides and Combinations (nateglinide, repaglinide +/- metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors and Combinations (canagliflozin +/- metformin, dapagliflozin +/- metformin, saxagliptin, empagliflozin +/- metformin, linagliptin, sitagliptin, etrugliflozin, simvastatin))

• BGP PQA STATIN MEDS
  - Statin Medications and Combinations (atorvastatin +/- amlodipine, ezetimibe], fluvastatin, lovastatin +/- niacin, pitavastatin, pravastatin, rosuvastatin, simvastatin +/- ezetimibe, niacin, sitagliptin))

• BGP PQA NON-WARFARIN ANTICOAG
  - Non-Warfarin Oral Anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)

• BGP PQA WARFARIN
  - Warfarin, Low Molecular Weight Heparin, Heparin, SC Factor Xa inhibitor (dalteparin, enoxaparin, fondaparinux, heparin, warfarin)
• BGP PQA ANTIRETROVIRAL MEDS

• BGP PQA ARB NEPRILYSIN INHIB
  – ARB/Neprilysin Inhibitor Combinations (sacubitril/valsartan)

• BGP PQA LA INHALED BRONCHO MED
  – Long-acting Inhaled Bronchodilator Medications and Combinations (aclidinium, formoterol [+- budesonide, glycopyrrolate], glycopyrrolate [+- formoterol], indacaterol [+- glycopyrrolate], olodaterol, salmeterol [+- fluticasone], tiotropium [+- olodaterol], umeclidinium [+- vilanterol, aclidinium], vilanterol [+- fluticasone, umeclidinium])

• BGP PQA NEBULIZED BRONCHO MEDS
  – Nebulized Bronchodilator Medications (albuterol sulfate, arformoterol tartrate, formoterol fumarate, glycopyrrolate, ipratropium bromide, ipratropium-albuterol, levalbuterol HCl)

• BGP PQA NON-INFUSED MS MEDS
  – Beta-Interferons (interferon beta 1a, interferon beta 1b, peginterferon beta-1a); Immunomodulators (daclizumab, fingolimid, glatiramer); Pyrimidine Synthesis Inhibitors (teriflunomide); Nrf2 Activators (dimethyl fumerate)

• BGP PQA INFUSED MS MEDS
  – Infused Disease Modifying Agents for MS (alemtuzumab, mitoxantrone, natalizumab, ocrelizumab)
ESRD

Any of the following ever:

- CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90918 through 90925 (old codes), 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90951 through 90970, 90989, 90993, 90997, 90999, 99512, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]

- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)

- Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6*; ICD-10 5A1D70Z, 5A1D80Z, 5A1D90Z [BGP ESRD PROCS]

Chronic Obstructive Pulmonary Disease (COPD)

Any of the following during the Report Period:

- COPD: Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 491.20, 491.21, 491.22, 493.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8 [BGP COPD DXS]
  - SNOMED data set PXRM BGP COPD (Problem List only)

- Emphysema: Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 492.*, 506.4, 518.1, 518.2; ICD-10: J43.*, J68.4, J68.8, J98.2, J98.3 [BGP EMPHYSEMA DXS]
  - SNOMED data set PXRM BGP EMPHYSEMA (Problem List only).

Hospice

- CPT 99377, 99378, G9473 through G9479, G9687, M1022, M1025, M1026, M1059, M1067 [BGP CPT HOSPICE]

- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

Each PDC Numerator

The PDC equals the number of days the patient was covered by at least one drug in the class divided by the number of days in the patient’s measurement period.
The patient’s measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

**Note:** If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:

- Rx Date: November 15, 2022
- Discontinued Date: November 19, 2022

Recalculated number of Days Prescribed:

November 19, 2022 – November 15, 2022 = 4

**Example of PDC**

Report Period: January 1 through December 31, 2022

- First prescription:
  - Index Rx Start Date: March 1, 2022
  - Days’ Supply: 90
  - Prescription covers patient through May 29, 2022

- Second prescription:
  - Rx Date: May 26, 2022
  - Days’ Supply: 90
  - Prescription covers patient through August 27, 2022

- Third prescription:
  - Rx Date: September 11, 2022
  - Days’ Supply: 180
  - Gap:
    
    \[
    September 11, 2022 - August 27, 2022 = 15 \text{ days}
    \]
    
    Prescription covers patient through March 8, 2023

Patient’s measurement period:

\[
March 1, 2022 \text{ through December 31, 2022} = 306 \text{ days}
\]

Days patient was covered:

\[
March 1, 2022 \text{ through August 27, 2022} +
September 11, 2022 \text{ through December 31, 2022} = 292 \text{ days}
\]
PDC:

\[292 \div 306 = 95\%\]

**Each Gap Numerator**

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days’ supply between consecutive medication fills.

**Example of Medication Gap 30 Days or Longer:**

Report Period: January 1 through December 31, 2022

- First prescription:
  - Rx Date: April 1, 2022
  - Days’ Supply: 30
  - Prescription covers patient through April 30, 2022

- Second prescription:
  - Rx Date: July 1, 2022
  - Days’ Supply: 90
  - Gap #1:
    
    \[July 1, 2022 - April 30, 2022 = 61 \text{ days}\]

  Prescription covers patient through September 28, 2022

- Third prescription:
  - Rx Date: October 1, 2022
  - Days’ Supply: 90
  - Gap #2:
    
    \[October 1, 2022 - September 28, 2022 = 2 \text{ days}\]

  Prescription covers patient through December 29, 2022

  \[Gap \#1 \geq 30 \text{ days}\]

Patient will be included in the numerator for that medication.

**2.7.1.6 Patient Lists**

- List of User Population patients aged 18 years and older whose PDC for beta blockers is 80% or more.
• List of User Population patients aged 18 years and older whose PDC for beta blockers is less than (<) 80%.

• List of User Population patients aged 18 years and older who had a gap of 30 days or more in their beta-blocker medication therapy.

• List of User Population patients aged 18 years and older whose PDC for RAS Antagonists is 80% or more.

• List of User Population patients aged 18 years and older whose PDC for RAS Antagonists is less than (<) 80%.

• List of User Population patients aged 18 years and older who had a gap of 30 days or more in their RAS Antagonist medication therapy.

• List of User Population patients aged 18 years and older whose PDC for CCBs is 80% or more.

• List of User Population patients aged 18 years and older whose PDC for CCBs is less than (<) 80%.

• List of User Population patients aged 18 years and older who had a gap of 30 days or more in their CCB medication therapy.

• List of User Population patients aged 18 years and older whose PDC for biguanides is 80% or more.

• List of User Population patients aged 18 years and older whose PDC for biguanides is less than (<) 80%.

• List of User Population patients aged 18 years and older who had a gap of 30 days or more in their biguanide medication therapy.

• List of User Population patients aged 18 years and older whose PDC for sulfonylureas is 80% or more.

• List of User Population patients aged 18 years and older whose PDC for sulfonylureas is less than (<) 80%.

• List of User Population patients aged 18 years and older who had a gap of 30 days or more in their sulfonylurea medication therapy.

• List of User Population patients aged 18 years and older whose PDC for thiazolidinediones is 80% or more.

• List of User Population patients aged 18 years and older whose PDC for thiazolidinediones is less than (<) 80%.

• List of User Population patients aged 18 and older who had a gap of 30 days or more in their thiazolidinedione medication therapy.
- List of User Population patients aged 18 years and older whose PDC for DPP-IV is greater than or equal to (≥) 80%.
- List of User Population patients aged 18 years and older whose PDC for DPP-IV is less than (<) 80%.
- List of User Population patients aged 18 years and older who had a gap greater than or equal to (≥) 30 days in their DPP-IV medication therapy.
- List of User Population patients aged 18 years and older whose PDC for Diabetes All Class is greater than or equal to (≥) 80%.
- List of User Population patients aged 18 years and older whose PDC for Diabetes All Class is less than (<) 80%.
- List of User Population patients aged 18 years and older who had a gap greater than or equal to (≥) 30 days in their Diabetes All Class medication therapy.
- List of User Population patients aged 18 years and older whose PDC for statins is 80% or more.
- List of User Population patients aged 18 years and older whose PDC for statins is less than (<) 80%.
- List of User Population patients aged 18 years and older who had a gap of 30 days or more in their statin medication therapy.
- List of User Population patients aged 18 years and older whose PDC for antiretroviral agents is 90% or more.
- List of User Population patients aged 18 years and older whose PDC for antiretroviral agents is less than (<) 90%.
- List of User Population patients with COPD whose proportion of days covered for long-acting inhaled bronchodilators is greater than or equal to (≥) 80%.
- List of User Population patients with COPD whose proportion of days covered for long-acting inhaled bronchodilators is less than (<) 80%.
- List of User Population patients 18 years and older whose proportion of days covered for non-infused disease modifying agents is greater than or equal to (≥) 80%.
- List of User Population patients 18 years and older whose proportion of days covered for non-infused disease modifying agents is less than (<) 80%.
2.7.2 Concurrent Use of Opioids and Benzodiazepines

2.7.2.1 Owner and Contact
Chris Lamer, PharmD

2.7.2.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.7.2.3 Denominators
1. Active Clinical patients aged 18 and older who had two or more prescriptions for opioids with total days’ supply of 15 or more and no cancer or hospice indicator during the Report Period.

2.7.2.4 Numerators
1. Patients who received two or more prescriptions for benzodiazepines with concurrent use of opioids and benzodiazepines for 30 or more cumulative days.

2.7.2.5 Definitions

Denominator
To be included in the denominator, patients must have at least two prescriptions for opioids on two unique dates of service at any time during the Report Period. The sum of the days’ supply must be 15 or more days during the Report Period.

Opioid Medications
Medication taxonomy BGP PQA OPIOID MEDS.
- Medications are (excludes injectable formulations): buprenorphine (excludes single-agent and combination buprenorphine products used to treat opioid use disorder), butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, pentazocine, tapentadol, tramadol). Medications must not have a comment of RETURNED TO STOCK.

Note: Outside medications and e-prescribed medications (prescription number begins with “X” or days’ supply is zero) will not be included in these measures.
Hospice
- CPT 99377, 99378, G9473 through G9479, G9687, M1022, M1025, M1026, M1059, M1067 [BGP CPT HOSPICE]
- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

Cancer
- POV ICD-9: 140.* through 172.*, 174.* through 209.3*, 209.7*, 235.* through 239.*; ICD-10: C00.* through C43.*, C4A.*, C45.0 through C96.*, D37.* through D49.*, Q85.0* [BGP PQA CANCER DXS]

Numerator
To be included in the numerator, patients must have at least two prescriptions for benzodiazepines on two unique dates of service at any time during the Report Period, with concurrent use of opioids and benzodiazepines for 30 or more cumulative days.

Concurrent use is identified using the dates of service and days’ supply of a patient’s opioid and benzodiazepine prescriptions. The days of concurrent use is the sum of the number of days during the treatment period with overlapping days’ supply for an opioid and a benzodiazepine.

Benzodiazepine Medications
Medication taxonomy BGP PQA BENZODIAZ OP MEDS.
- Medications are (excludes injectable formulations): alprazolam, clordiazepoxide, clorazapam, cloraepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, triazolam. Medications must not have a comment of RETURNED TO STOCK.

Note: Outside medications and e-prescribed medications (prescription number begins with “X” or days’ supply is zero) will not be included in these measures.

2.7.2.6 Patient Lists
- List of Active Clinical patients aged 18 years and older with two or more prescriptions for opioids with 30 or more days of concurrent use of benzodiazepines.
- List of Active Clinical patients aged 18 years and older with two or more prescriptions for opioids without 30 or more days of concurrent use of benzodiazepines.
2.7.3 Medication Therapy Management Services

2.7.3.1 Owner and Contact
Chris Lamer, PharmD

2.7.3.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.7.3.3 Denominators
1. Active Clinical patients 18 and older with Medications dispensed at their facility during the Report Period.

2.7.3.4 Numerators
1. Patients who received Medication Therapy Management (MTM) during the Report Period.

2.7.3.5 Definitions
Patients Receiving Medications
Identified by any entry in the VMed file for your facility.

MTM
• CPT 99605 through 99607 [BGP CPT MTM]
• Clinic codes: D1, D2, D5

2.7.3.6 Patient List
• List of Active Clinical patients aged 18 years and older receiving medications with medication therapy management.
• List of Active Clinical patients aged 18 years and older receiving medications without medication therapy management.

2.7.4 Optometry

2.7.4.1 Owner and Contact
Dr. Dawn Clary
2.7.4.2 National Reporting

NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.7.4.3 Denominators

1. GPRA Developmental (NQF 0086): Active Clinical patients aged 18 years and older with a diagnosis of primary open-angle glaucoma during the Report Period.

2.7.4.4 Numerators

1. GPRA Developmental (NQF 0086): Patients with an optic nerve head evaluation during the Report Period.

2.7.4.5 Definitions

Primary Open-Angle Glaucoma

Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):

- SNOMED data set PXRM OPEN ANGLE GLAUCOMA (Problem List only)

Optic Nerve Head Evaluation

CPT: 2027F [BGP OPTIC NERVE HEAD EVAL CPT]

2.7.4.6 Patient Lists

- List of Active Clinical patients aged 18 years and older with primary open-angle glaucoma and optic nerve head evaluation.
- List of Active Clinical patients aged 18 years and older with primary open-angle glaucoma and no optic nerve head evaluation.
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Term Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADA</td>
<td>American Dental Association</td>
</tr>
<tr>
<td>AI/AN</td>
<td>American Indian/Alaska Native</td>
</tr>
<tr>
<td>AMI</td>
<td>Acute Myocardial Infarction</td>
</tr>
<tr>
<td>ASA</td>
<td>Acetylsalicylic Acid</td>
</tr>
<tr>
<td>BH</td>
<td>Behavioral Health</td>
</tr>
<tr>
<td>BHS</td>
<td>Behavioral Health System</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary Artery Bypass Graft</td>
</tr>
<tr>
<td>CCB</td>
<td>Calcium Channel Blockers</td>
</tr>
<tr>
<td>CD4</td>
<td>Cluster Difference 4</td>
</tr>
<tr>
<td>CHD</td>
<td>Coronary Heart Disease</td>
</tr>
<tr>
<td>CPT</td>
<td>Current Procedural Terminology</td>
</tr>
<tr>
<td>CRS</td>
<td>Clinical Reporting System</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular Disease</td>
</tr>
<tr>
<td>CVX</td>
<td>Vaccine Code</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>DPST</td>
<td>Demo/Test Patient Search Template</td>
</tr>
<tr>
<td>DTaP</td>
<td>Diphtheria Tetanus Acellular Pertussis</td>
</tr>
<tr>
<td>EDD</td>
<td>Earliest Due Date</td>
</tr>
<tr>
<td>EGA</td>
<td>Estimated Gestational Age</td>
</tr>
<tr>
<td>ER</td>
<td>Emergency Room</td>
</tr>
<tr>
<td>ESRD</td>
<td>End Stage Renal Disease</td>
</tr>
<tr>
<td>EX</td>
<td>Exercise</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GPRA</td>
<td>Government Performance and Results Act of 1993</td>
</tr>
<tr>
<td>GPRAMA</td>
<td>GPRA Modernization Act</td>
</tr>
<tr>
<td>HEDIS</td>
<td>Healthcare Effectiveness Data and Information Set</td>
</tr>
<tr>
<td>HiB</td>
<td>Haemophilus Influenzae Type B</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HPV</td>
<td>Human Papilloma Virus</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>Acronym</td>
<td>Term Meaning</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>IMM</td>
<td>Immunization</td>
</tr>
<tr>
<td>LOINC</td>
<td>Logical Observations Identifiers, Names, Codes</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low Molecular Weight Heparin</td>
</tr>
<tr>
<td>MTM</td>
<td>Medication Therapy Management</td>
</tr>
<tr>
<td>NMI</td>
<td>Not Medically Indicated</td>
</tr>
<tr>
<td>OMB</td>
<td>Office of Management and Budget</td>
</tr>
<tr>
<td>PCC</td>
<td>Patient Care Component</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous Coronary Interventions</td>
</tr>
<tr>
<td>POV</td>
<td>Purpose of Visit</td>
</tr>
<tr>
<td>PRC</td>
<td>Purchased and Referred Care</td>
</tr>
<tr>
<td>RPMS</td>
<td>Resource and Patient Management System</td>
</tr>
<tr>
<td>SNOMED</td>
<td>Systemized Nomenclature of Medicine</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually Transmitted Infection</td>
</tr>
<tr>
<td>SUD</td>
<td>Substance Use Disorder</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient Ischemic Attack</td>
</tr>
</tbody>
</table>
Contact Information

If you have any questions or comments regarding this distribution, please contact the IHS IT Service Desk.

Phone: (888) 830-7280 (toll free)
Web: https://www.ihs.gov/itsupport/
Email: itsupport@ihs.gov